{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:25:50Z","timestamp":1794104750006,"version":"4.8.0"},"reference-count":287,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272661"],"award-info":[{"award-number":["82272661"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Foundation of Liaoning key special project of Science and Technology","award":["2022JH1\/10800070"],"award-info":[{"award-number":["2022JH1\/10800070"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01927-5","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T07:05:29Z","timestamp":1765263929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Role of the tumor microenvironment in chemotherapy resistance in ovarian cancer and targeted therapy"],"prefix":"10.1186","volume":"19","author":[{"given":"Rui","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiapeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"1927_CR1","doi-asserted-by":"publisher","first-page":"m3773","DOI":"10.1136\/bmj.m3773","volume":"371","author":"L Kuroki","year":"2020","unstructured":"Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773. https:\/\/doi.org\/10.1136\/bmj.m3773.","journal-title":"BMJ"},{"key":"1927_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100629","volume":"33","author":"S Sambasivan","year":"2022","unstructured":"Sambasivan S. Epithelial ovarian cancer: review article. Cancer Treat Res Commun. 2022;33:100629. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100629.","journal-title":"Cancer Treat Res Commun"},{"issue":"5","key":"1927_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21(5):389\u2013400. https:\/\/doi.org\/10.1038\/s41571-024-00881-3.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"1927_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126532","volume":"22","author":"S Morand","year":"2021","unstructured":"Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian cancer immunotherapy and personalized medicine. Int J Mol Sci. 2021;22(12):6532. https:\/\/doi.org\/10.3390\/ijms22126532.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1927_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2217\/fon-2019-0042","volume":"16","author":"CE Haunschild","year":"2020","unstructured":"Haunschild CE, Tewari KS. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Future Oncol. 2020;16(7):225\u201346. https:\/\/doi.org\/10.2217\/fon-2019-0042.","journal-title":"Future Oncol"},{"issue":"1","key":"1927_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13048-019-0579-0","volume":"12","author":"S Gupta","year":"2019","unstructured":"Gupta S, Nag S, Aggarwal S, Rauthan A, Warrier N. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review. J Ovarian Res. 2019;12(1):103. https:\/\/doi.org\/10.1186\/s13048-019-0579-0.","journal-title":"J Ovarian Res"},{"issue":"4","key":"1927_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284\u201396. https:\/\/doi.org\/10.3322\/caac.21456.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1927_CR8","doi-asserted-by":"publisher","DOI":"10.3892\/or.2022.8293","volume":"47","author":"L Yang","year":"2022","unstructured":"Yang L, Xie HJ, Li YY, Wang X, Liu XX, Mai J. Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (review). Oncol Rep. 2022;47(4):82. https:\/\/doi.org\/10.3892\/or.2022.8293.","journal-title":"Oncol Rep"},{"issue":"8","key":"1927_CR9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.clon.2020.03.005","volume":"32","author":"MW Wong-Brown","year":"2020","unstructured":"Wong-Brown MW, van der Westhuizen A, Bowden NA. Targeting DNA repair in ovarian cancer treatment resistance. Clin Oncol (R Coll Radiol). 2020;32(8):518\u201326. https:\/\/doi.org\/10.1016\/j.clon.2020.03.005.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"5","key":"1927_CR10","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3390\/cells9051299","volume":"9","author":"M Nowak","year":"2020","unstructured":"Nowak M, Klink M. The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer. Cells. 2020;9(5):1299. https:\/\/doi.org\/10.3390\/cells9051299.","journal-title":"Cells"},{"issue":"2","key":"1927_CR11","first-page":"181","volume":"38","author":"A Markowska","year":"2017","unstructured":"Markowska A, Sajdak S. Role of cancer stem cells and microRNA in resistance to chemotherapy in patients with ovarian cancer. Eur J Gynaecol Oncol. 2017;38(2):181\u20133.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"2","key":"1927_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188361","volume":"1873","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Wang C, Zhou S. Targeting tumor microenvironment in ovarian cancer: premise and promise. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2020;1873(2):188361. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188361.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"8","key":"1927_CR13","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s13238-017-0466-7","volume":"9","author":"B Zhang","year":"2018","unstructured":"Zhang B, Chen F, Xu Q, Han L, Xu J, Gao L, et al. Revisiting ovarian cancer microenvironment: a friend or a foe? Protein Cell. 2018;9(8):674\u201392. https:\/\/doi.org\/10.1007\/s13238-017-0466-7.","journal-title":"Protein Cell"},{"key":"1927_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656364","volume":"12","author":"K Khalaf","year":"2021","unstructured":"Khalaf K, Hana D, Chou JT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol. 2021;12:656364. https:\/\/doi.org\/10.3389\/fimmu.2021.656364.","journal-title":"Front Immunol"},{"issue":"2","key":"1927_CR15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.semcancer.2022.03.028","volume":"86","author":"S Bose","year":"2022","unstructured":"Bose S, Saha P, Chatterjee B, Srivastava AK. Chemokines driven ovarian cancer progression, metastasis and chemoresistance: potential pharmacological targets for cancer therapy. Semin Cancer Biol. 2022;86(2):568\u201379. https:\/\/doi.org\/10.1016\/j.semcancer.2022.03.028.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"1927_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10238-006-0117-4","volume":"6","author":"D Ribatti","year":"2006","unstructured":"Ribatti D, Mangialardi G, Vacca A. Stephen Paget and the \u201cseed and soil\u201d theory of metastatic dissemination. Clin Exp Med. 2006;6(4):145\u20139. https:\/\/doi.org\/10.1007\/s10238-006-0117-4.","journal-title":"Clin Exp Med"},{"issue":"16","key":"1927_CR17","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1158\/1078-0432.CCR-22-0296","volume":"28","author":"J Xu","year":"2022","unstructured":"Xu J, Fang Y, Chen K, Li S, Tang S, Ren Y, et al. Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer. Clin Cancer Res. 2022;28(16):3590\u2013602. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0296.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1927_CR18","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1158\/0008-5472.CAN-22-1821","volume":"83","author":"S Ferri-Borgogno","year":"2023","unstructured":"Ferri-Borgogno S, Zhu Y, Sheng J, Burks JK, Gomez JA, Wong KK, et al. Spatial transcriptomics depict ligand-receptor cross-talk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors. Cancer Res. 2023;83(9):1503\u201316. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-1821.","journal-title":"Cancer Res"},{"issue":"1","key":"1927_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131. https:\/\/doi.org\/10.1186\/s12943-021-01428-1.","journal-title":"Mol Cancer"},{"issue":"1","key":"1927_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12943-022-01682-x","volume":"21","author":"P Nallasamy","year":"2022","unstructured":"Nallasamy P, Nimmakayala RK, Parte S, Are AC, Batra SK, Ponnusamy MP. Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis. Mol Cancer. 2022;21(1):225. https:\/\/doi.org\/10.1186\/s12943-022-01682-x.","journal-title":"Mol Cancer"},{"key":"1927_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104119","volume":"353","author":"LQ Fu","year":"2020","unstructured":"Fu LQ, Du WL, Cai MH, Yao JY, Zhao YY, Mou XZ. The roles of tumor-associated macrophages in tumor angiogenesis and metastasis. Cell Immunol. 2020;353:104119. https:\/\/doi.org\/10.1016\/j.cellimm.2020.104119.","journal-title":"Cell Immunol"},{"issue":"3","key":"1927_CR22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41(3):421\u201333. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.009.","journal-title":"Cancer Cell"},{"issue":"1","key":"1927_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.pan.2016.12.010","volume":"17","author":"P Dauer","year":"2017","unstructured":"Dauer P, Nomura A, Saluja A, Banerjee S. Microenvironment in determining chemo-resistance in pancreatic cancer: neighborhood matters. Pancreatology. 2017;17(1):7\u201312. https:\/\/doi.org\/10.1016\/j.pan.2016.12.010.","journal-title":"Pancreatology"},{"issue":"4949 Pt 1","key":"1927_CR24","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.247.4949.1457","volume":"247","author":"BA Teicher","year":"1990","unstructured":"Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW, et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 1990;247(4949 Pt 1):1457\u201361. https:\/\/doi.org\/10.1126\/science.247.4949.1457.","journal-title":"Science"},{"key":"1927_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/IJN.S441135","volume":"19","author":"C Peng","year":"2024","unstructured":"Peng C, Xu Y, Wu J, Wu D, Zhou L, Xia X. TME-related biomimetic strategies against cancer. Int J Nanomedicine. 2024;19:109\u201335. https:\/\/doi.org\/10.2147\/IJN.S441135.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"1927_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","volume":"18","author":"H Jia","year":"2025","unstructured":"Jia H, Chen X, Zhang L, Chen M. Cancer associated fibroblasts in cancer development and therapy. J Hematol Oncol. 2025;18(1):36. https:\/\/doi.org\/10.1186\/s13045-025-01688-0.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1927_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071586","volume":"18","author":"DA Senthebane","year":"2017","unstructured":"Senthebane DA, Rowe A, Thomford NE, Shipanga H, Munro D, Mazeedi MAMA, et al. The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int J Mol Sci. 2017;18(7):1586. https:\/\/doi.org\/10.3390\/ijms18071586.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1927_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19102861","volume":"19","author":"DA Senthebane","year":"2018","unstructured":"Senthebane DA, Jonker T, Rowe A, Thomford NE, Munro D, Dandara C, et al. The role of tumor microenvironment in chemoresistance: 3D extracellular matrices as accomplices. Int J Mol Sci. 2018;19(10):2861. https:\/\/doi.org\/10.3390\/ijms19102861.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1927_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12929-022-00888-x","volume":"29","author":"SC Lin","year":"2022","unstructured":"Lin SC, Liao YC, Chen PM, Yang YY, Wang YH, Tung SL, et al. Periostin promotes ovarian cancer metastasis by enhancing M2 macrophages and cancer-associated fibroblasts via integrin-mediated NF-\u03baB and TGF-\u03b22 signaling. J Biomed Sci. 2022;29(1):109. https:\/\/doi.org\/10.1186\/s12929-022-00888-x.","journal-title":"J Biomed Sci"},{"key":"1927_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215946","volume":"551","author":"BY Jeong","year":"2022","unstructured":"Jeong BY, Cho KH, Jeong KJ, Cho SJ, Won M, Kim SH, et al. Lysophosphatidic acid-induced amphiregulin secretion by cancer-associated fibroblasts augments cancer cell invasion. Cancer Lett. 2022;551:215946. https:\/\/doi.org\/10.1016\/j.canlet.2022.215946.","journal-title":"Cancer Lett"},{"issue":"1","key":"1927_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12392","volume":"43","author":"Z Fang","year":"2023","unstructured":"Fang Z, Meng Q, Xu J, Wang W, Zhang B, Liu J, et al. Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives. Cancer Commun. 2023;43(1):3\u201341. https:\/\/doi.org\/10.1002\/cac2.12392.","journal-title":"Cancer Commun"},{"issue":"1","key":"1927_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s13105-022-00899-0","volume":"79","author":"LN Barrera","year":"2023","unstructured":"Barrera LN, Ridley PM, Bermejo-Rodriguez C, Costello E, Perez-Mancera PA. The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis. J Physiol Biochem. 2023;79(1):193\u2013204. https:\/\/doi.org\/10.1007\/s13105-022-00899-0.","journal-title":"J Physiol Biochem"},{"issue":"3","key":"1927_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2174\/1871530323666230823094556","volume":"24","author":"S Anajafi","year":"2024","unstructured":"Anajafi S, Paryan M, Khoshnazar A, Soleimani M, Mohammadi-Yeganeh S. MiRNAs delivery for cancer-associated fibroblasts\u2019 activation and drug resistance in cancer microenvironment. Endocr Metab Immune Disord Drug Targets. 2024;24(3):333\u201347. https:\/\/doi.org\/10.2174\/1871530323666230823094556.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"1927_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2023.04.059","volume":"662","author":"K Wojtowicz","year":"2023","unstructured":"Wojtowicz K, Nowicki M. The characterization of the sensitive ovarian cancer cell lines A2780 and W1 in response to ovarian CAFs. Biochem Biophys Res Commun. 2023;662:1\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2023.04.059.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"1927_CR35","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/s41416-021-01680-8","volume":"126","author":"B Darvishi","year":"2022","unstructured":"Darvishi B, Eisavand MR, Majidzadeh-A K, Farahmand L. Matrix stiffening and acquired resistance to chemotherapy: concepts and clinical significance. Br J Cancer. 2022;126(9):1253\u201363. https:\/\/doi.org\/10.1038\/s41416-021-01680-8.","journal-title":"Br J Cancer"},{"issue":"1","key":"1927_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-022-01252-0","volume":"15","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Zhang H, Wang J, Liu Y, Luo T, Hua H. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol. 2022;15(1):34. https:\/\/doi.org\/10.1186\/s13045-022-01252-0.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1927_CR37","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41419-022-05129-5","volume":"13","author":"Y Jin","year":"2022","unstructured":"Jin Y, Bian S, Wang H, Mo J, Fei H, Li L, et al. CRMP2 derived from cancer associated fibroblasts facilitates progression of ovarian cancer via HIF-1\u03b1-glycolysis signaling pathway. Cell Death Dis. 2022;13(8):675. https:\/\/doi.org\/10.1038\/s41419-022-05129-5.","journal-title":"Cell Death Dis"},{"key":"1927_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.796588","volume":"11","author":"RM Escalona","year":"2022","unstructured":"Escalona RM, Kannourakis G, Findlay JK, Ahmed N. Expression of TIMPs and MMPs in ovarian tumors, ascites, ascites-derived cells, and cancer cell lines: characteristic modulatory response before and after chemotherapy treatment. Front Oncol. 2022;11:796588. https:\/\/doi.org\/10.3389\/fonc.2021.796588.","journal-title":"Front Oncol"},{"issue":"3","key":"1927_CR39","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1002\/jcb.27681","volume":"120","author":"M Najafi","year":"2019","unstructured":"Najafi M, Farhood B, Mortezaee K. Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J Cell Biochem. 2019;120(3):2782\u201390. https:\/\/doi.org\/10.1002\/jcb.27681.","journal-title":"J Cell Biochem"},{"issue":"2","key":"1927_CR40","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20160470","volume":"37","author":"W Deying","year":"2017","unstructured":"Deying W, Feng G, Shumei L, Hui Z, Ming L, Hongqing W. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met\/PI3K\/Akt and GRP78 signalling in ovarian cancer cells. Biosci Rep. 2017;37(2):BSR20160470. https:\/\/doi.org\/10.1042\/BSR20160470.","journal-title":"Biosci Rep"},{"issue":"1","key":"1927_CR41","doi-asserted-by":"publisher","first-page":"16231","DOI":"10.1038\/s41598-017-13431-y","volume":"7","author":"D Zhang","year":"2017","unstructured":"Zhang D, Ding L, Li Y, Ren J, Shi G, Wang Y, et al. Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumour cells. Sci Rep. 2017;7(1):16231. https:\/\/doi.org\/10.1038\/s41598-017-13431-y.","journal-title":"Sci Rep"},{"issue":"5","key":"1927_CR42","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3892\/ijo.2016.3442","volume":"48","author":"B Zhou","year":"2016","unstructured":"Zhou B, Sun C, Li N, Shan W, Lu H, Guo L, et al. Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K\/Akt signaling pathways. Int J Oncol. 2016;48(5):2087\u201397. https:\/\/doi.org\/10.3892\/ijo.2016.3442.","journal-title":"Int J Oncol"},{"issue":"32","key":"1927_CR43","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.2217\/fon-2020-0095","volume":"16","author":"F Zhang","year":"2020","unstructured":"Zhang F, Cui JY, Gao HF, Yu H, Gao FF, Chen JL, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12\/CXCR4 axis. Future Oncol. 2020;16(32):2619\u201333. https:\/\/doi.org\/10.2217\/fon-2020-0095.","journal-title":"Future Oncol"},{"issue":"1","key":"1927_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1019-x","volume":"18","author":"JL Hu","year":"2019","unstructured":"Hu JL, Wang W, Lan XL, Zeng ZC, Liang YS, Yan YR, et al. CAfs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019;18(1):91. https:\/\/doi.org\/10.1186\/s12943-019-1019-x.","journal-title":"Mol Cancer"},{"issue":"1","key":"1927_CR45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/biomedicines11010112","volume":"11","author":"R Sulaiman","year":"2023","unstructured":"Sulaiman R, De P, Aske JC, Lin X, Dale A, Koirala N, et al. Patient-derived primary cancer-associated fibroblasts mediate resistance to anti-angiogenic drug in ovarian cancers. Biomedicines. 2023;11(1):112. https:\/\/doi.org\/10.3390\/biomedicines11010112.","journal-title":"Biomedicines"},{"key":"1927_CR46","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.csbj.2022.12.049","volume":"21","author":"J Zhang","year":"2022","unstructured":"Zhang J, Lu T, Lu S, Ma S, Han D, Zhang K, et al. Single-cell analysis of multiple cancer types reveals differences in endothelial cells between tumors and normal tissues. Comput Struct Biotechnol J. 2022;21:665\u201376. https:\/\/doi.org\/10.1016\/j.csbj.2022.12.049.","journal-title":"Comput Struct Biotechnol J"},{"issue":"3","key":"1927_CR47","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/cac2.12274","volume":"42","author":"Z Wang","year":"2022","unstructured":"Wang Z, Chen W, Zuo L, Xu M, Wu Y, Huang J, et al. The fibrillin-1\/VEGFR2\/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells. Cancer Commun. 2022;42(3):245\u201365. https:\/\/doi.org\/10.1002\/cac2.12274.","journal-title":"Cancer Commun"},{"issue":"4","key":"1927_CR48","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.bbrc.2016.01.131","volume":"470","author":"H Yan","year":"2016","unstructured":"Yan H, Guo BY, Zhang S. Cancer-associated fibroblasts attenuate cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling. Biochem Biophys Res Commun. 2016;470(4):947\u201354. https:\/\/doi.org\/10.1016\/j.bbrc.2016.01.131.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1927_CR49","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1172\/JCI95200","volume":"128","author":"CS Leung","year":"2018","unstructured":"Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, et al. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest. 2018;128(2):589\u2013606. https:\/\/doi.org\/10.1172\/JCI95200.","journal-title":"J Clin Invest"},{"key":"1927_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109052","volume":"110","author":"H Ding","year":"2022","unstructured":"Ding H, Zhang J, Zhang F, Xu Y, Yu Y, Liang W, et al. Role of cancer-associated fibroblast in the pathogenesis of ovarian cancer: focus on the latest therapeutic approaches. Int Immunopharmacol. 2022;110:109052. https:\/\/doi.org\/10.1016\/j.intimp.2022.109052.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1927_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00523-y","volume":"8","author":"Y Hu","year":"2024","unstructured":"Hu Y, Recouvreux MS, Haro M, Taylan E, Taylor-Harding B, Walts AE, et al. INHBA(+) cancer-associated fibroblasts generate an immunosuppressive tumor microenvironment in ovarian cancer. NPJ Precis Oncol. 2024;8(1):35. https:\/\/doi.org\/10.1038\/s41698-024-00523-y.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"1927_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12307-014-0153-7","volume":"8","author":"P Mhawech-Fauceglia","year":"2015","unstructured":"Mhawech-Fauceglia P, Yan L, Sharifian M, Ren X, Liu S, Kim G, et al. Stromal expression of fibroblast activation protein alpha (FAP) predicts platinum resistance and shorter recurrence in patients with epithelial ovarian cancer. Cancer Microenviron. 2015;8(1):23\u201331. https:\/\/doi.org\/10.1007\/s12307-014-0153-7.","journal-title":"Cancer Microenviron"},{"issue":"6","key":"1927_CR53","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25(6):735\u201347. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.021.","journal-title":"Cancer Cell"},{"issue":"15","key":"1927_CR54","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.1158\/0008-5472.CAN-13-0062","volume":"73","author":"M Murakami","year":"2013","unstructured":"Murakami M, Ernsting MJ, Undzys E, Holwell N, Foltz WD, Li SD. Docetaxel conjugate nanoparticles that target \u03b1-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Res. 2013;73(15):4862\u201371. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0062.","journal-title":"Cancer Res"},{"issue":"5","key":"1927_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101532","volume":"5","author":"Y Mori","year":"2024","unstructured":"Mori Y, Okimoto Y, Sakai H, Kanda Y, Ohata H, Shiokawa D, et al. Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1\u03b1 and tumor progression of clear cell ovarian cancer. Cell Rep Med. 2024;5(5):101532. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101532.","journal-title":"Cell Rep Med"},{"key":"1927_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216700","volume":"588","author":"J Liu","year":"2024","unstructured":"Liu J, Liu C, Ma Y, Pan X, Chu R, Yao S, et al. STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs). Cancer Lett. 2024;588:216700. https:\/\/doi.org\/10.1016\/j.canlet.2024.216700.","journal-title":"Cancer Lett"},{"issue":"21","key":"1927_CR57","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-19-0187","volume":"25","author":"TL Yeung","year":"2019","unstructured":"Yeung TL, Leung CS, Yip KP, Sheng J, Vien L, Bover LC, et al. Anticancer immunotherapy by MFAP5 blockade inhibits fibrosis and enhances chemosensitivity in ovarian and pancreatic cancer. Clin Cancer Res. 2019;25(21):6417\u201328. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0187.","journal-title":"Clin Cancer Res"},{"key":"1927_CR58","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.canlet.2018.11.023","volume":"442","author":"R Radhakrishnan","year":"2019","unstructured":"Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley KM, Isidoro C, et al. Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. Cancer Lett. 2019;442:464\u201374. https:\/\/doi.org\/10.1016\/j.canlet.2018.11.023.","journal-title":"Cancer Lett"},{"key":"1927_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12630","volume":"7","author":"A Chronopoulos","year":"2016","unstructured":"Chronopoulos A, Robinson B, Sarper M, Cortes E, Auernheimer V, Lachowski D, et al. Atra mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion. Nat Commun. 2016;7:12630. https:\/\/doi.org\/10.1038\/ncomms12630.","journal-title":"Nat Commun"},{"issue":"1","key":"1927_CR60","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","volume":"159","author":"MH Sherman","year":"2014","unstructured":"Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159(1):80\u201393. https:\/\/doi.org\/10.1016\/j.cell.2014.08.007.","journal-title":"Cell"},{"key":"1927_CR61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.semcancer.2020.12.024","volume":"77","author":"A Ghoneum","year":"2021","unstructured":"Ghoneum A, Almousa S, Warren B, Abdulfattah AY, Shu J, Abouelfadl H, et al. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer. Semin Cancer Biol. 2021;77:83\u201398. https:\/\/doi.org\/10.1016\/j.semcancer.2020.12.024.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1927_CR62","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-020-00887-1","volume":"13","author":"CS Lu","year":"2020","unstructured":"Lu CS, Shiau AL, Su BH, Hsu TS, Wang CT, Su YC, et al. Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer. J Hematol Oncol. 2020;13(1):62. https:\/\/doi.org\/10.1186\/s13045-020-00887-1.","journal-title":"J Hematol Oncol"},{"key":"1927_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113474","volume":"153","author":"YI Yang","year":"2022","unstructured":"Yang YI, Wang YY, Ahn JH, Kim BH, Choi JH. CCL2 overexpression is associated with paclitaxel resistance in ovarian cancer cells via autocrine signaling and macrophage recruitment. Biomed Pharmacother. 2022;153:113474. https:\/\/doi.org\/10.1016\/j.biopha.2022.113474.","journal-title":"Biomed Pharmacother"},{"issue":"28","key":"1927_CR64","doi-asserted-by":"publisher","first-page":"43076","DOI":"10.18632\/oncotarget.9246","volume":"7","author":"X Ying","year":"2016","unstructured":"Ying X, Wu Q, Wu X, Zhu Q, Wang X, Jiang L, et al. Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 2016;7(28):43076\u201387. https:\/\/doi.org\/10.18632\/oncotarget.9246.","journal-title":"Oncotarget"},{"issue":"1","key":"1927_CR65","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3892\/or.2017.5697","volume":"38","author":"X Chen","year":"2017","unstructured":"Chen X, Ying X, Wang X, Wu X, Zhu Q, Wang X. Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA-940 to induce macrophage M2 polarization. Oncol Rep. 2017;38(1):522\u20138. https:\/\/doi.org\/10.3892\/or.2017.5697.","journal-title":"Oncol Rep"},{"issue":"1","key":"1927_CR66","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13048-021-00826-9","volume":"14","author":"J Xiong","year":"2021","unstructured":"Xiong J, He X, Xu Y, Zhang W, Fu F. Mir-200b is upregulated in plasma-derived exosomes and functions as an oncogene by promoting macrophage M2 polarization in ovarian cancer. J Ovarian Res. 2021;14(1):74. https:\/\/doi.org\/10.1186\/s13048-021-00826-9.","journal-title":"J Ovarian Res"},{"issue":"1","key":"1927_CR67","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13048-025-01616-3","volume":"18","author":"L He","year":"2025","unstructured":"He L, Chen Q, Wu X. Tumour-derived exosomal miR-205 promotes ovarian cancer cell progression through M2 macrophage polarization via the PI3K\/Akt\/mTOR pathway. J Ovarian Res. 2025;18(1):28. https:\/\/doi.org\/10.1186\/s13048-025-01616-3.","journal-title":"J Ovarian Res"},{"issue":"3","key":"1927_CR68","doi-asserted-by":"publisher","first-page":"e004029","DOI":"10.1136\/jitc-2021-004029","volume":"10","author":"H Li","year":"2022","unstructured":"Li H, Luo F, Jiang X, Zhang W, Xiang T, Pan Q, et al. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype. J Immunother Cancer. 2022;10(3):e004029. https:\/\/doi.org\/10.1136\/jitc-2021-004029.","journal-title":"J Immunother Cancer"},{"key":"1927_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.123810","volume":"237","author":"X Fang","year":"2023","unstructured":"Fang X, Zhao P, Gao S, Liu D, Zhang S, Shan M, et al. Lactate induces tumor-associated macrophage polarization independent of mitochondrial pyruvate carrier-mediated metabolism. Int J Biol Macromol. 2023;237:123810. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.123810.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"1927_CR70","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00280-023-04533-8","volume":"92","author":"L Hong","year":"2023","unstructured":"Hong L, Wang X, Zheng L, Wang S, Zhu G. Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16\/CXCR6 axis. Cancer Chemother Pharmacol. 2023;92(1):71\u201381. https:\/\/doi.org\/10.1007\/s00280-023-04533-8.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1927_CR71","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-019-1095-1","volume":"38","author":"X Zhu","year":"2019","unstructured":"Zhu X, Shen H, Yin X, Yang M, Wei H, Chen Q, et al. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Exp Clin Cancer Res. 2019;38(1):81. https:\/\/doi.org\/10.1186\/s13046-019-1095-1.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"1927_CR72","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1021\/acs.molpharmaceut.2c00557","volume":"20","author":"C Chen","year":"2023","unstructured":"Chen C, Zhang L, Ruan Z. GATA3 encapsulated by tumor-associated macrophage-derived extracellular vesicles promotes immune escape and chemotherapy resistance of ovarian cancer cells by upregulating the CD24\/Siglec-10 axis. Mol Pharm. 2023;20(2):971\u201386. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00557.","journal-title":"Mol Pharm"},{"issue":"37","key":"1927_CR73","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1038\/s41388-018-0317-x","volume":"37","author":"S Al Habyan","year":"2018","unstructured":"Al Habyan S, Kalos C, Szymborski J, McCaffrey L. Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer. Oncogene. 2018;37(37):5127\u201335. https:\/\/doi.org\/10.1038\/s41388-018-0317-x.","journal-title":"Oncogene"},{"key":"1927_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00137","volume":"4","author":"EK Colvin","year":"2014","unstructured":"Colvin EK. Tumor-Associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol. 2014;4:137. https:\/\/doi.org\/10.3389\/fonc.2014.00137.","journal-title":"Front Oncol"},{"issue":"3","key":"1927_CR75","doi-asserted-by":"publisher","first-page":"100989","DOI":"10.1016\/j.gendis.2023.04.023","volume":"11","author":"M Yu","year":"2023","unstructured":"Yu M, Wu Y, Li Q, Hong W, Yang Y, Hu X, et al. Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer. Genes Dis. 2023;11(3):100989. https:\/\/doi.org\/10.1016\/j.gendis.2023.04.023.","journal-title":"Genes Dis"},{"issue":"1","key":"1927_CR76","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1038\/s41467-021-23164-2","volume":"12","author":"YC Wang","year":"2021","unstructured":"Wang YC, Wang X, Yu J, Ma F, Li Z, Zhou Y, et al. Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy. Nat Commun. 2021;12(1):3530. https:\/\/doi.org\/10.1038\/s41467-021-23164-2.","journal-title":"Nat Commun"},{"issue":"1","key":"1927_CR77","doi-asserted-by":"publisher","first-page":"2261242","DOI":"10.1080\/2162402X.2023.2261242","volume":"12","author":"C Zhang","year":"2023","unstructured":"Zhang C, Cao K, Yang M, Wang Y, He M, Lu J, et al. C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer. Oncoimmunology. 2023;12(1):2261242. https:\/\/doi.org\/10.1080\/2162402X.2023.2261242.","journal-title":"Oncoimmunology"},{"issue":"11","key":"1927_CR78","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41419-023-06301-1","volume":"14","author":"S Wang","year":"2023","unstructured":"Wang S, Liu Y, Xiao H, Chen Z, Yang X, Yin J, et al. Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with \u03b1PDL1 in ovarian cancer. Cell Death Dis. 2023;14(11):775. https:\/\/doi.org\/10.1038\/s41419-023-06301-1.","journal-title":"Cell Death Dis"},{"issue":"9","key":"1927_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007099","volume":"11","author":"Y Wang","year":"2023","unstructured":"Wang Y, He M, Zhang C, Cao K, Zhang G, Yang M. <article-title update=\"added\">Siglec-9 + tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer. J Immunother Cancer. 2023;11(9):e007099. https:\/\/doi.org\/10.1136\/jitc-2023-007099.","journal-title":"J Immunother Cancer"},{"key":"1927_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114906","volume":"160","author":"L Hou","year":"2025","unstructured":"Hou L, Jiang M, Li Y, Cheng J, Liu F, Han X. Targeting SPP1+ macrophages via the SPP1-CD44 axis reveals a key mechanism of immune suppression and tumor progression in ovarian cancer. Int Immunopharmacol. 2025;160:114906. https:\/\/doi.org\/10.1016\/j.intimp.2025.114906.","journal-title":"Int Immunopharmacol"},{"issue":"15","key":"1927_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412881","volume":"12","author":"J Xiong","year":"2025","unstructured":"Xiong J, Huang J, Xu H, Wu Q, Zhao J, Chen Y, et al. Cpg-based nanovaccines enhance ovarian cancer immune response by Gbp2-mediated remodeling of tumor-associated macrophages. Adv Sci. 2025;12(15):e2412881. https:\/\/doi.org\/10.1002\/advs.202412881.","journal-title":"Adv Sci"},{"issue":"1","key":"1927_CR82","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s13578-023-01149-6","volume":"13","author":"J Wang","year":"2023","unstructured":"Wang J, Ling D, Shi L, Li H, Peng M, Wen H, et al. METTL3-mediated m6A methylation regulates ovarian cancer progression by recruiting myeloid-derived suppressor cells. Cell Biosci. 2023;13(1):202. https:\/\/doi.org\/10.1186\/s13578-023-01149-6.","journal-title":"Cell Biosci"},{"issue":"1","key":"1927_CR83","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/s41467-018-03966-7","volume":"9","author":"M Taki","year":"2018","unstructured":"Taki M, Abiko K, Baba T, Hamanishi J, Yamaguchi K, Murakami R, et al. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat Commun. 2018;9(1):1685. https:\/\/doi.org\/10.1038\/s41467-018-03966-7.","journal-title":"Nat Commun"},{"issue":"24","key":"1927_CR84","doi-asserted-by":"publisher","first-page":"7463","DOI":"10.1158\/0008-5472.CAN-11-2449","volume":"71","author":"N Obermajer","year":"2011","unstructured":"Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011;71(24):7463\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2449.","journal-title":"Cancer Res"},{"issue":"44","key":"1927_CR85","doi-asserted-by":"publisher","first-page":"76843","DOI":"10.18632\/oncotarget.20164","volume":"8","author":"L Wu","year":"2017","unstructured":"Wu L, Deng Z, Peng Y, Han L, Liu J, Wang L, et al. Ascites-derived IL-6 and IL-10 synergistically expand CD14+HLA-DR-\/low myeloid-derived suppressor cells in ovarian cancer patients. Oncotarget. 2017;8(44):76843\u201356. https:\/\/doi.org\/10.18632\/oncotarget.20164.","journal-title":"Oncotarget"},{"issue":"9","key":"1927_CR86","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.7150\/ijbs.70013","volume":"18","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang Q, Wu M, Zhang P, Huang L, Ai X, et al. Suppressing MDSC infiltration in tumor microenvironment serves as an option for treating ovarian cancer metastasis. Int J Biol Sci. 2022;18(9):3697\u2013713. https:\/\/doi.org\/10.7150\/ijbs.70013.","journal-title":"Int J Biol Sci"},{"key":"1927_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0154-9","volume":"4","author":"I Montalb\u00e1n Del Barrio","year":"2016","unstructured":"Montalb\u00e1n Del Barrio I, Penski C, Schlahsa L, Stein RG, Diessner J, W\u00f6ckel A, et al. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape. J Immunother Cancer. 2016;4:49. https:\/\/doi.org\/10.1186\/s40425-016-0154-9.","journal-title":"J Immunother Cancer"},{"key":"1927_CR88","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3389\/fimmu.2019.00691","volume":"10","author":"K Ok\u0142a","year":"2019","unstructured":"Ok\u0142a K, Czerwonka A, Wawruszak A, Bobi\u0144ski M, Bilska M, Tarkowski R, et al. Clinical relevance and immunosuppressive pattern of circulating and infiltrating subsets of myeloid-derived suppressor cells (MDSCs) in epithelial ovarian cancer. Front Immunol. 2019;10:691. https:\/\/doi.org\/10.3389\/fimmu.2019.00691.","journal-title":"Front Immunol"},{"issue":"3","key":"1927_CR89","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/jmcb\/mjz090","volume":"12","author":"A Le Naour","year":"2020","unstructured":"Le Naour A, Prat M, Thibault B, et al. Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors. J Mol Cell Biol. 2020;12(3):202\u201315. https:\/\/doi.org\/10.1093\/jmcb\/mjz090.","journal-title":"J Mol Cell Biol"},{"issue":"6","key":"1927_CR90","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41416-019-0725-x","volume":"122","author":"N Horikawa","year":"2020","unstructured":"Horikawa N, Abiko K, Matsumura N, Baba T, Hamanishi J, Yamaguchi K, et al. Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment. Br J Cancer. 2020;122(6):778\u201388. https:\/\/doi.org\/10.1038\/s41416-019-0725-x.","journal-title":"Br J Cancer"},{"issue":"10","key":"1927_CR91","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1038\/s41418-023-01209-x","volume":"30","author":"B Ducarouge","year":"2023","unstructured":"Ducarouge B, Redavid AR, Victoor C, Chira R, Fonseca A, Hervieu M, et al. Netrin-1 blockade inhibits tumor associated myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor. Cell Death Differ. 2023;30(10):2201\u201312. https:\/\/doi.org\/10.1038\/s41418-023-01209-x.","journal-title":"Cell Death Differ"},{"key":"1927_CR92","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150. https:\/\/doi.org\/10.1038\/ncomms12150.","journal-title":"Nat Commun"},{"issue":"8","key":"1927_CR93","doi-asserted-by":"publisher","first-page":"e1465166","DOI":"10.1080\/2162402X.2018.1465166","volume":"7","author":"SJAM Santegoets","year":"2018","unstructured":"Santegoets SJAM, de Groot AF, Dijkgraaf EM, Sim\u00f5es AMC, van der Noord VE, van Ham JJ, et al. The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival. Oncoimmunology. 2018;7(8):e1465166. https:\/\/doi.org\/10.1080\/2162402X.2018.1465166.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1927_CR94","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1476-5381.2009.00182.x","volume":"158","author":"ME Bradley","year":"2009","unstructured":"Bradley ME, Bond ME, Manini J, Brown Z, Charlton SJ. SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor [published correction appears in Br J Pharmacol. 2009;158(3):931. doi: 10.1111\/j.1476-5381.2009.00182.x. Br J Pharmacol. 2009;158(1):328\u201338.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"1927_CR95","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2213-2600(16)30227-2","volume":"4","author":"PM O'Byrne","year":"2016","unstructured":"O\u2019Byrne PM, Metev H, Puu M, Richter K, Keen C, Uddin M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4(10):797\u2013806. https:\/\/doi.org\/10.1016\/S2213-2600(16)30227-2.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"1927_CR96","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s10637-019-00875-4","volume":"38","author":"S Lapointe","year":"2020","unstructured":"Lapointe S, Mason W, MacNeil M, Harlos C, Tsang R, Sederias J, et al. A phase I study of vistusertib (dual mTORC1\/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study. Invest New Drugs. 2020;38(4):1137\u201344. https:\/\/doi.org\/10.1007\/s10637-019-00875-4.","journal-title":"Invest New Drugs"},{"issue":"22","key":"1927_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225520","volume":"14","author":"A Bouyahya","year":"2022","unstructured":"Bouyahya A, El Allam A, Aboulaghras S, Bakrim S, El Menyiy N, Alshahrani MM, et al. Targeting mTOR as a cancer therapy: recent advances in natural bioactive compounds and immunotherapy. Cancers (Basel). 2022;14(22):5520. https:\/\/doi.org\/10.3390\/cancers14225520.","journal-title":"Cancers (Basel)"},{"key":"1927_CR98","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.canlet.2021.09.017","volume":"523","author":"R Pi","year":"2021","unstructured":"Pi R, Yang Y, Hu X, Li H, Shi H, Liu Y, et al. Dual mTORC1\/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth. Cancer Lett. 2021;523:72\u201381. https:\/\/doi.org\/10.1016\/j.canlet.2021.09.017.","journal-title":"Cancer Lett"},{"issue":"5","key":"1927_CR99","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamaoncol.2022.7966","volume":"9","author":"S Banerjee","year":"2023","unstructured":"Banerjee S, Giannone G, Clamp AR, Ennis DP, Glasspool RM, Herbertson R, et al. Efficacy and safety of weekly paclitaxel plus vistusertib vs paclitaxel alone in patients with platinum-resistant ovarian high-grade serous carcinoma: the OCTOPUS multicenter, phase 2, randomized clinical trial. JAMA Oncol. 2023;9(5):675\u201382. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7966.","journal-title":"JAMA Oncol"},{"issue":"12","key":"1927_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122881","volume":"14","author":"J Kang","year":"2022","unstructured":"Kang J, Lee D, Lee KJ, Yoon JE, Kwon JH, Seo Y, et al. Tumor-suppressive effect of metformin via the regulation of M2 macrophages and myeloid-derived suppressor cells in the tumor microenvironment of colorectal cancer. Cancers (Basel). 2022;14(12):2881. https:\/\/doi.org\/10.3390\/cancers14122881.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1927_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020867","volume":"22","author":"FK Tsogas","year":"2021","unstructured":"Tsogas FK, Majerczyk D, Hart PC. Possible role of metformin as an immune modulator in the tumor microenvironment of ovarian cancer. Int J Mol Sci. 2021;22(2):867. https:\/\/doi.org\/10.3390\/ijms22020867.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1927_CR102","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2165\/00003495-200059040-00017","volume":"59","author":"D Clemett","year":"2000","unstructured":"Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs. 2000;59(4):957\u201380. https:\/\/doi.org\/10.2165\/00003495-200059040-00017.","journal-title":"Drugs"},{"issue":"4","key":"1927_CR103","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1158\/2326-6066.CIR-15-0157","volume":"4","author":"JL Wong","year":"2016","unstructured":"Wong JL, Obermajer N, Odunsi K, Edwards RP, Kalinski P. Synergistic COX2 induction by IFN\u03b3 and TNF\u03b1 self-limits type-1 immunity in the human tumor microenvironment. Cancer Immunol Res. 2016;4(4):303\u201311. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0157.","journal-title":"Cancer Immunol Res"},{"key":"1927_CR104","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/1471-2407-11-214","volume":"11","author":"F Legge","year":"2011","unstructured":"Legge F, Paglia A, D\u2019Asta M, Fuoco G, Scambia G, Ferrandina G. Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. BMC Cancer. 2011;11:214. https:\/\/doi.org\/10.1186\/1471-2407-11-214.","journal-title":"BMC Cancer"},{"issue":"3","key":"1927_CR105","doi-asserted-by":"publisher","first-page":"e010959","DOI":"10.1136\/jitc-2024-010959","volume":"13","author":"OO Yeku","year":"2025","unstructured":"Yeku OO, Barve M, Tan WW, Wang J, Patnaik A, LoRusso P, et al. Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer. J Immunother Cancer. 2025;13(3):e010959. https:\/\/doi.org\/10.1136\/jitc-2024-010959.","journal-title":"J Immunother Cancer"},{"issue":"14","key":"1927_CR106","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3390\/cells12141912","volume":"12","author":"K Ok\u0142a","year":"2023","unstructured":"Ok\u0142a K. Myeloid-derived suppressor cells (MDSCs) in ovarian cancer-looking back and forward. Cells. 2023;12(14):1912. https:\/\/doi.org\/10.3390\/cells12141912.","journal-title":"Cells"},{"key":"1927_CR107","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fphys.2018.00113","volume":"9","author":"C Rosales","year":"2018","unstructured":"Rosales C. Neutrophil: a cell with many roles in inflammation or several cell types? Front Physiol. 2018;9:113. https:\/\/doi.org\/10.3389\/fphys.2018.00113.","journal-title":"Front Physiol"},{"issue":"4","key":"1927_CR108","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/s1074-7613(03)00263-2","volume":"19","author":"C Martin","year":"2003","unstructured":"Martin C, Burdon PC, Bridger G, Gutierrez-Ramos JC, Williams TJ, Rankin SM. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity. 2003;19(4):583\u201393. https:\/\/doi.org\/10.1016\/s1074-7613(03)00263-2.","journal-title":"Immunity"},{"issue":"3","key":"1927_CR109","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","volume":"16","author":"ZG Fridlender","year":"2009","unstructured":"Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. <article-title update=\"added\">Polarization of tumor-associated neutrophil phenotype by TGF-\u03b2: \u201cN1\u201d versus \u201cN2\u201d TAN. Cancer Cell. 2009;16(3):183\u201394. https:\/\/doi.org\/10.1016\/j.ccr.2009.06.017.","journal-title":"Cancer Cell"},{"key":"1927_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01146","volume":"9","author":"MT Masucci","year":"2019","unstructured":"Masucci MT, Minopoli M, Carriero MV. Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. Front Oncol. 2019;9:1146. https:\/\/doi.org\/10.3389\/fonc.2019.01146.","journal-title":"Front Oncol"},{"issue":"10","key":"1927_CR111","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41571-019-0222-4","volume":"16","author":"ME Shaul","year":"2019","unstructured":"Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601\u201320. https:\/\/doi.org\/10.1038\/s41571-019-0222-4.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"1927_CR112","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/14728222.2021.1954162","volume":"25","author":"TM Bui","year":"2021","unstructured":"Bui TM, Yalom LK, Sumagin R. Tumor-associated neutrophils: orchestrating cancer pathobiology and therapeutic resistance. Expert Opin Ther Targets. 2021;25(7):573\u201383. https:\/\/doi.org\/10.1080\/14728222.2021.1954162.","journal-title":"Expert Opin Ther Targets"},{"key":"1927_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.947183","volume":"12","author":"M Zippoli","year":"2022","unstructured":"Zippoli M, Ruocco A, Novelli R, Rocchio F, Miscione MS, Allegretti M, et al. The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance. Front Oncol. 2022;12:947183. https:\/\/doi.org\/10.3389\/fonc.2022.947183.","journal-title":"Front Oncol"},{"issue":"9","key":"1927_CR114","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/s41416-020-1026-0","volume":"123","author":"M Yang","year":"2020","unstructured":"Yang M, Zhang G, Wang Y, He M, Xu Q, Lu J, et al. Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer. Br J Cancer. 2020;123(9):1404\u201316. https:\/\/doi.org\/10.1038\/s41416-020-1026-0.","journal-title":"Br J Cancer"},{"key":"1927_CR115","doi-asserted-by":"publisher","first-page":"867516","DOI":"10.3389\/fimmu.2022.867516","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Liu F, Chen L, Fang C, Li S, Yuan S, et al. Neutrophil extracellular traps (NETs) promote non-small cell lung cancer metastasis by suppressing lncRNA MIR503HG to activate the NF-\u03baB\/NLRP3 inflammasome pathway. Front Immunol. 2022;13:867516. https:\/\/doi.org\/10.3389\/fimmu.2022.867516.","journal-title":"Front Immunol"},{"issue":"3","key":"1927_CR116","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ccell.2023.02.001","volume":"41","author":"JM Adrover","year":"2023","unstructured":"Adrover JM, McDowell SAC, He XY, Quail DF, Egeblad M. Networking with cancer: the bidirectional interplay between cancer and neutrophil extracellular traps. Cancer Cell. 2023;41(3):505\u201326. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.001.","journal-title":"Cancer Cell"},{"key":"1927_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102906","volume":"67","author":"C Chu","year":"2023","unstructured":"Chu C, Wang X, Yang C, Chen F, Shi L, Xu W, et al. Neutrophil extracellular traps drive intestinal microvascular endothelial ferroptosis by impairing Fundc1-dependent mitophagy. Redox Biol. 2023;67:102906. https:\/\/doi.org\/10.1016\/j.redox.2023.102906.","journal-title":"Redox Biol"},{"issue":"4","key":"1927_CR118","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ccell.2023.03.011","volume":"41","author":"PE Saw","year":"2023","unstructured":"Saw PE, Chen J, Song E. Chemonetosis: a road to tumor therapeutic resistance. Cancer Cell. 2023;41(4):655\u20137. https:\/\/doi.org\/10.1016\/j.ccell.2023.03.011.","journal-title":"Cancer Cell"},{"issue":"4","key":"1927_CR119","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2023.03.008","volume":"41","author":"A Mousset","year":"2023","unstructured":"Mousset A, Lecorgne E, Bourget I, Lopez P, Jenovai K, Cherfils-Vicini J, et al. Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-\u03b2 activation. Cancer Cell. 2023;41(4):757-775.e10. https:\/\/doi.org\/10.1016\/j.ccell.2023.03.008.","journal-title":"Cancer Cell"},{"issue":"9","key":"1927_CR120","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","volume":"20","author":"S Jaillon","year":"2020","unstructured":"Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485\u2013503. https:\/\/doi.org\/10.1038\/s41568-020-0281-y.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1927_CR121","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/cac2.12613","volume":"45","author":"J Yao","year":"2025","unstructured":"Yao J, Ji L, Wang G, Ding J. Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms. Cancer Commun. 2025;45(1):15\u201342. https:\/\/doi.org\/10.1002\/cac2.12613.","journal-title":"Cancer Commun"},{"key":"1927_CR122","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3389\/fimmu.2019.02278","volume":"10","author":"I Terr\u00e9n","year":"2019","unstructured":"Terr\u00e9n I, Orrantia A, Vitall\u00e9 J, Zenarruzabeitia O, Borrego F. NK cell metabolism and tumor microenvironment. Front Immunol. 2019;10:2278. https:\/\/doi.org\/10.3389\/fimmu.2019.02278.","journal-title":"Front Immunol"},{"issue":"7976","key":"1927_CR123","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41586-023-06421-w","volume":"620","author":"ZRC Marks","year":"2023","unstructured":"Marks ZRC, Campbell NK, Mangan NE, Vandenberg CJ, Gearing LJ, Matthews AY, et al. Interferon-\u03b5 is a tumour suppressor and restricts ovarian cancer. Nature. 2023;620(7976):1063\u201370. https:\/\/doi.org\/10.1038\/s41586-023-06421-w.","journal-title":"Nature"},{"issue":"4","key":"1927_CR124","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1007\/s13277-015-4313-2","volume":"37","author":"A Labani-Motlagh","year":"2016","unstructured":"Labani-Motlagh A, Israelsson P, Ottander U, et al. Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity. Tumor Biol. 2016;37(4):5455\u201366. https:\/\/doi.org\/10.1007\/s13277-015-4313-2.","journal-title":"Tumor Biol"},{"issue":"8","key":"1927_CR125","first-page":"9428","volume":"8","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Xu Y, Chen L, Xu B, Wu C, Jiang J. B7\u2013H6 expression correlates with cancer progression and patient\u2019s survival in human ovarian cancer. Int J Clin Exp Pathol. 2015;8(8):9428\u201333.","journal-title":"Int J Clin Exp Pathol"},{"issue":"15","key":"1927_CR126","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1158\/0008-5472.CAN-12-4366","volume":"73","author":"JL Wong","year":"2013","unstructured":"Wong JL, Berk E, Edwards RP, Kalinski P. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res. 2013;73(15):4653\u201362. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-4366.","journal-title":"Cancer Res"},{"issue":"1","key":"1927_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01014-w","volume":"14","author":"S Liu","year":"2021","unstructured":"Liu S, Galat V, Galat Y, Lee YKA, Wainwright D, Wu J. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021;14(1):7. https:\/\/doi.org\/10.1186\/s13045-020-01014-w.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"1927_CR128","doi-asserted-by":"publisher","first-page":"7338","DOI":"10.4049\/jimmunol.180.11.7338","volume":"180","author":"M Krockenberger","year":"2008","unstructured":"Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, H\u00f6nig A, H\u00e4usler S, et al. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol. 2008;180(11):7338\u201348. https:\/\/doi.org\/10.4049\/jimmunol.180.11.7338.","journal-title":"J Immunol"},{"key":"1927_CR129","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3389\/fimmu.2019.01782","volume":"10","author":"S Nersesian","year":"2019","unstructured":"Nersesian S, Glazebrook H, Toulany J, Grantham SR, Boudreau JE. Naturally killing the silent killer: NK cell-based immunotherapy for ovarian cancer. Front Immunol. 2019;10:1782. https:\/\/doi.org\/10.3389\/fimmu.2019.01782.","journal-title":"Front Immunol"},{"issue":"1","key":"1927_CR130","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13046-023-02798-8","volume":"42","author":"A Hrvat","year":"2023","unstructured":"Hrvat A, Schmidt M, Wagner B, Zwanziger D, Kimmig R, Volbracht L, et al. Electrolyte imbalance causes suppression of NK and T cell effector function in malignant ascites. J Exp Clin Cancer Res. 2023;42(1):235. https:\/\/doi.org\/10.1186\/s13046-023-02798-8.","journal-title":"J Exp Clin Cancer Res"},{"issue":"107","key":"1927_CR131","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adr4795","volume":"10","author":"K Slattery","year":"2025","unstructured":"Slattery K, Yao CH, Mylod E, Scanlan J, Scott B, Crowley JP, et al. Uptake of lipids from ascites drives NK cell metabolic dysfunction in ovarian cancer. Sci Immunol. 2025;10(107):eadr4795. https:\/\/doi.org\/10.1126\/sciimmunol.adr4795.","journal-title":"Sci Immunol"},{"key":"1927_CR132","doi-asserted-by":"publisher","first-page":"1087689","DOI":"10.3389\/fimmu.2022.1087689","volume":"13","author":"H Luo","year":"2023","unstructured":"Luo H, Zhou Y, Zhang J, Zhang Y, Long S, Lin X, et al. NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions. Front Immunol. 2023;13:1087689. https:\/\/doi.org\/10.3389\/fimmu.2022.1087689.","journal-title":"Front Immunol"},{"issue":"12","key":"1927_CR133","doi-asserted-by":"publisher","first-page":"e005026","DOI":"10.1136\/jitc-2022-005026","volume":"10","author":"R Raja","year":"2022","unstructured":"Raja R, Wu C, Bassoy EY, Rubino TE Jr, Utagawa EC, Magtibay PM, et al. PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling. J Immunother Cancer. 2022;10(12):e005026. https:\/\/doi.org\/10.1136\/jitc-2022-005026.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1927_CR134","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/intimm\/dxv041","volume":"27","author":"YY Siew","year":"2015","unstructured":"Siew YY, Neo SY, Yew HC, Lim SW, Ng YC, Lew SM, et al. Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity. Int Immunol. 2015;27(12):621\u201332. https:\/\/doi.org\/10.1093\/intimm\/dxv041.","journal-title":"Int Immunol"},{"issue":"5","key":"1927_CR135","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.7150\/ijbs.88539","volume":"20","author":"J Li","year":"2024","unstructured":"Li J, Hu H, Lian H, Yang S, Liu M, He J, et al. NK-92MI cells engineered with anti-claudin-6 chimeric antigen receptors in immunotherapy for ovarian cancer. Int J Biol Sci. 2024;20(5):1578\u2013601. https:\/\/doi.org\/10.7150\/ijbs.88539.","journal-title":"Int J Biol Sci"},{"key":"1927_CR136","doi-asserted-by":"publisher","first-page":"1039969","DOI":"10.3389\/fimmu.2022.1039969","volume":"13","author":"SK Nikkhoi","year":"2023","unstructured":"Nikkhoi SK, Li G, Eleya S, Yang G, Vandavasi VG, Hatefi A. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy. Front Immunol. 2023;13:1039969. https:\/\/doi.org\/10.3389\/fimmu.2022.1039969.","journal-title":"Front Immunol"},{"issue":"9","key":"1927_CR137","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942\u20139. https:\/\/doi.org\/10.1038\/nm1093.","journal-title":"Nat Med"},{"issue":"11","key":"1927_CR138","doi-asserted-by":"publisher","first-page":"e80063","DOI":"10.1371\/journal.pone.0080063","volume":"8","author":"CC Preston","year":"2013","unstructured":"Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, et al. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One. 2013;8(11):e80063. https:\/\/doi.org\/10.1371\/journal.pone.0080063.","journal-title":"PLoS One"},{"issue":"18","key":"1927_CR139","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1016\/j.cell.2024.06.013","volume":"187","author":"Y Luo","year":"2024","unstructured":"Luo Y, Xia Y, Liu D, Li X, Li H, Liu J, et al. Neoadjuvant PARpi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell. 2024;187(18):4905-4925.e24. https:\/\/doi.org\/10.1016\/j.cell.2024.06.013.","journal-title":"Cell"},{"issue":"12","key":"1927_CR140","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/2326-6066.CIR-17-0479","volume":"6","author":"J Zhou","year":"2018","unstructured":"Zhou J, Li X, Wu X, Zhang T, Zhu Q, Wang X, et al. Exosomes released from tumor-associated macrophages transfer miRNAs that induce a Treg\/Th17 cell imbalance in epithelial ovarian cancer. Cancer Immunol Res. 2018;6(12):1578\u201392. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0479.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1927_CR141","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41419-020-03272-5","volume":"12","author":"R Xu","year":"2021","unstructured":"Xu R, Wu M, Liu S, Shang W, Li R, Xu J, et al. Glucose metabolism characteristics and TLR8-mediated metabolic control of CD4+ Treg cells in ovarian cancer cells microenvironment. Cell Death Dis. 2021;12(1):22. https:\/\/doi.org\/10.1038\/s41419-020-03272-5.","journal-title":"Cell Death Dis"},{"issue":"22","key":"1927_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225488","volume":"14","author":"E Cassar","year":"2022","unstructured":"Cassar E, Kartikasari AER, Plebanski M. Regulatory t cells in ovarian carcinogenesis and future therapeutic opportunities. Cancers (Basel). 2022;14(22):5488. https:\/\/doi.org\/10.3390\/cancers14225488.","journal-title":"Cancers (Basel)"},{"issue":"14","key":"1927_CR143","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1158\/0008-5472.CAN-12-0721","volume":"72","author":"J Emmerich","year":"2012","unstructured":"Emmerich J, Mumm JB, Chan IH, LaFace D, Truong H, McClanahan T, et al. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res. 2012;72(14):3570\u201381. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0721.","journal-title":"Cancer Res"},{"issue":"1","key":"1927_CR144","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/1078-0432.CCR-23-0771","volume":"30","author":"B Tavira","year":"2024","unstructured":"Tavira B, Iscar T, Manso L, Santaballa A, Gil-Martin M, Garc\u00eda Garc\u00eda Y, et al. Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T\/MINOVA study). Clin Cancer Res. 2024;30(1):176\u201386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0771.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1927_CR145","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00262-008-0628-9","volume":"58","author":"RG van der Most","year":"2009","unstructured":"van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, et al. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother. 2009;58(8):1219\u201328. https:\/\/doi.org\/10.1007\/s00262-008-0628-9.","journal-title":"Cancer Immunol Immunother"},{"key":"1927_CR146","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.3389\/fimmu.2019.02453","volume":"10","author":"CM Paluskievicz","year":"2019","unstructured":"Paluskievicz CM, Cao X, Abdi R, Zheng P, Liu Y, Bromberg JS. T regulatory cells and priming the suppressive tumor microenvironment. Front Immunol. 2019;10:2453. https:\/\/doi.org\/10.3389\/fimmu.2019.02453.","journal-title":"Front Immunol"},{"issue":"9","key":"1927_CR147","doi-asserted-by":"publisher","first-page":"e85974","DOI":"10.1172\/jci.insight.85974","volume":"1","author":"T Courau","year":"2016","unstructured":"Courau T, Nehar-Belaid D, Florez L, Levacher B, Vazquez T, Brimaud F, et al. TGF-\u03b2 and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. JCI Insight. 2016;1(9):e85974. https:\/\/doi.org\/10.1172\/jci.insight.85974.","journal-title":"JCI Insight"},{"issue":"7","key":"1927_CR148","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41591-018-0070-2","volume":"24","author":"E Trotta","year":"2018","unstructured":"Trotta E, Bessette PH, Silveria SL, Ely LK, Jude KM, Le DT, et al. A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. Nat Med. 2018;24(7):1005\u201314. https:\/\/doi.org\/10.1038\/s41591-018-0070-2.","journal-title":"Nat Med"},{"issue":"4","key":"1927_CR149","doi-asserted-by":"publisher","first-page":"e003892","DOI":"10.1136\/jitc-2021-003892","volume":"10","author":"A Revenko","year":"2022","unstructured":"Revenko A, Carnevalli LS, Sinclair C, Johnson B, Peter A, Taylor M, et al. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer. J Immunother Cancer. 2022;10(4):e003892. https:\/\/doi.org\/10.1136\/jitc-2021-003892.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1927_CR150","doi-asserted-by":"publisher","first-page":"e1090075","DOI":"10.1080\/2162402X.2015.1090075","volume":"5","author":"DK Chang","year":"2015","unstructured":"Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, et al. Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2015;5(3):e1090075. https:\/\/doi.org\/10.1080\/2162402X.2015.1090075.","journal-title":"Oncoimmunology"},{"issue":"462","key":"1927_CR151","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaf8608","volume":"10","author":"H Torrey","year":"2017","unstructured":"Torrey H, Butterworth J, Mera T, Okubo Y, Wang L, Baum D, et al. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci Signal. 2017;10(462):eaaf8608. https:\/\/doi.org\/10.1126\/scisignal.aaf8608.","journal-title":"Sci Signal"},{"issue":"13","key":"1927_CR152","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1158\/1078-0432.CCR-20-4594","volume":"27","author":"SR Thibodeaux","year":"2021","unstructured":"Thibodeaux SR, Barnett BB, Pandeswara S, Wall SR, Hurez V, Dao V, et al. IFN\u03b1 augments clinical efficacy of regulatory T-cell depletion with denileukin diftitox in ovarian cancer. Clin Cancer Res. 2021;27(13):3661\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4594.","journal-title":"Clin Cancer Res"},{"key":"1927_CR153","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ctrv.2015.11.005","volume":"42","author":"MT Madondo","year":"2016","unstructured":"Madondo MT, Quinn M, Plebanski M. Low dose cyclophosphamide: mechanisms of T cell modulation. Cancer Treat Rev. 2016;42:3\u20139. https:\/\/doi.org\/10.1016\/j.ctrv.2015.11.005.","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"1927_CR154","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-06-2347","volume":"13","author":"SA Perez","year":"2007","unstructured":"Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, Iliopoulou EG, et al. CD4+CD25+ regulatory T-cell frequency in HER-2\/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res. 2007;13(9):2714\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2347.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1927_CR155","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1158\/0008-5472.CAN-05-1797","volume":"65","author":"LA Emens","year":"2005","unstructured":"Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 2005;65(18):8059\u201364. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1797.","journal-title":"Cancer Res"},{"issue":"4","key":"1927_CR156","doi-asserted-by":"publisher","first-page":"C762","DOI":"10.1152\/ajpcell.00022.2022","volume":"322","author":"R Gupta","year":"2022","unstructured":"Gupta R. Epigenetic regulation and targeting of ECM for cancer therapy. Am J Physiol Cell Physiol. 2022;322(4):C762-8. https:\/\/doi.org\/10.1152\/ajpcell.00022.2022.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"19","key":"1927_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20194947","volume":"20","author":"M Paolillo","year":"2019","unstructured":"Paolillo M, Schinelli S. Extracellular matrix alterations in metastatic processes. Int J Mol Sci. 2019;20(19):4947. https:\/\/doi.org\/10.3390\/ijms20194947.","journal-title":"Int J Mol Sci"},{"key":"1927_CR158","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/978-3-319-49674-0_14","volume":"82","author":"J Bella","year":"2017","unstructured":"Bella J, Hulmes DJ. Fibrillar Collagens. Subcell Biochem. 2017;82:457\u201390. https:\/\/doi.org\/10.1007\/978-3-319-49674-0_14.","journal-title":"Subcell Biochem"},{"issue":"10","key":"1927_CR159","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.7150\/jca.15371","volume":"7","author":"R Januchowski","year":"2016","unstructured":"Januchowski R, \u015awierczewska M, Sterzy\u0144ska K, Wojtowicz K, Nowicki M, Zabel M. Increased expression of several collagen genes is associated with drug resistance in ovarian cancer cell lines. J Cancer. 2016;7(10):1295\u2013310. https:\/\/doi.org\/10.7150\/jca.15371.","journal-title":"J Cancer"},{"issue":"10","key":"1927_CR160","doi-asserted-by":"publisher","first-page":"6907","DOI":"10.1002\/jcp.30350","volume":"236","author":"J Zhang","year":"2021","unstructured":"Zhang J, Zhang J, Wang F, Xu X, Li X, Guan W, et al. Overexpressed COL5A1 is correlated with tumor progression, paclitaxel resistance, and tumor-infiltrating immune cells in ovarian cancer. J Cell Physiol. 2021;236(10):6907\u201319. https:\/\/doi.org\/10.1002\/jcp.30350.","journal-title":"J Cell Physiol"},{"issue":"5","key":"1927_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050935","volume":"13","author":"S Nallanthighal","year":"2021","unstructured":"Nallanthighal S, Heiserman JP, Cheon DJ. Collagen type XI alpha 1 (COL11A1): a novel biomarker and a key player in cancer. Cancers (Basel). 2021;13(5):935. https:\/\/doi.org\/10.3390\/cancers13050935.","journal-title":"Cancers (Basel)"},{"key":"1927_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.925165","volume":"12","author":"YH Wu","year":"2022","unstructured":"Wu YH, Chou CY. Collagen XI alpha 1 chain, a novel therapeutic target for cancer treatment. Front Oncol. 2022;12:925165. https:\/\/doi.org\/10.3389\/fonc.2022.925165.","journal-title":"Front Oncol"},{"issue":"35","key":"1927_CR163","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1038\/s41388-018-0297-x","volume":"37","author":"M Rada","year":"2018","unstructured":"Rada M, Nallanthighal S, Cha J, Ryan K, Sage J, Eldred C, et al. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer. Oncogene. 2018;37(35):4809\u201320. https:\/\/doi.org\/10.1038\/s41388-018-0297-x.","journal-title":"Oncogene"},{"issue":"1","key":"1927_CR164","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12967-022-03776-y","volume":"20","author":"D Leung","year":"2022","unstructured":"Leung D, Price ZK, Lokman NA, Wang W, Goonetilleke L, Kadife E, et al. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism. J Transl Med. 2022;20(1):556. https:\/\/doi.org\/10.1186\/s12967-022-03776-y.","journal-title":"J Transl Med"},{"issue":"3","key":"1927_CR165","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1042\/EBC20180050","volume":"63","author":"SD Vallet","year":"2019","unstructured":"Vallet SD, Ricard-Blum S. Lysyl oxidases: from enzyme activity to extracellular matrix cross-links. Essays Biochem. 2019;63(3):349\u201364. https:\/\/doi.org\/10.1042\/EBC20180050.","journal-title":"Essays Biochem"},{"issue":"10","key":"1927_CR166","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19102901","volume":"19","author":"K Sterzy\u0144ska","year":"2018","unstructured":"Sterzy\u0144ska K, Klejewski A, Wojtowicz K, et al. The role of matrix gla protein (MGP) expression in Paclitaxel and Topotecan resistant ovarian cancer cell lines. Int J Mol Sci. 2018;19(10):2901. https:\/\/doi.org\/10.3390\/ijms19102901.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1927_CR167","doi-asserted-by":"publisher","first-page":"11677","DOI":"10.1038\/s41598-019-47871-5","volume":"9","author":"S Wang","year":"2019","unstructured":"Wang S, Jia J, Liu D, Wang M, Wang Z, Li X, et al. Matrix metalloproteinase expressions play important role in prediction of ovarian cancer outcome. Sci Rep. 2019;9(1):11677. https:\/\/doi.org\/10.1038\/s41598-019-47871-5.","journal-title":"Sci Rep"},{"issue":"5","key":"1927_CR168","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00404-020-05858-y","volume":"303","author":"C Dai","year":"2021","unstructured":"Dai C, Xu P, Liu S, Xu S, Xu J, Fu Z, et al. Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells. Arch Gynecol Obstet. 2021;303(5):1271\u201381. https:\/\/doi.org\/10.1007\/s00404-020-05858-y.","journal-title":"Arch Gynecol Obstet"},{"issue":"18","key":"1927_CR169","doi-asserted-by":"publisher","first-page":"26806","DOI":"10.18632\/oncotarget.8645","volume":"7","author":"T Mariya","year":"2016","unstructured":"Mariya T, Hirohashi Y, Torigoe T, Tabuchi Y, Asano T, Saijo H, et al. Matrix metalloproteinase-10 regulates stemness of ovarian cancer stem-like cells by activation of canonical Wnt signaling and can be a target of chemotherapy-resistant ovarian cancer. Oncotarget. 2016;7(18):26806\u201322. https:\/\/doi.org\/10.18632\/oncotarget.8645.","journal-title":"Oncotarget"},{"issue":"26","key":"1927_CR170","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473\u201383. https:\/\/doi.org\/10.1056\/NEJMoa1104390.","journal-title":"N Engl J Med"},{"issue":"19","key":"1927_CR171","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194987","volume":"13","author":"M Kretschmer","year":"2021","unstructured":"Kretschmer M, R\u00fcdiger D, Zahler S. Mechanical aspects of angiogenesis. Cancers (Basel). 2021;13(19):4987. https:\/\/doi.org\/10.3390\/cancers13194987.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1927_CR172","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10456-021-09804-7","volume":"25","author":"M Bao","year":"2022","unstructured":"Bao M, Chen Y, Liu JT, Bao H, Wang WB, Qi YX, et al. Extracellular matrix stiffness controls VEGF165 secretion and neuroblastoma angiogenesis via the YAP\/RUNX2\/SRSF1 axis. Angiogenesis. 2022;25(1):71\u201386. https:\/\/doi.org\/10.1007\/s10456-021-09804-7.","journal-title":"Angiogenesis"},{"issue":"8","key":"1927_CR173","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1073\/pnas.97.8.3884","volume":"97","author":"J Fang","year":"2000","unstructured":"Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A. 2000;97(8):3884\u20139. https:\/\/doi.org\/10.1073\/pnas.97.8.3884.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1927_CR174","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.matbio.2015.04.004","volume":"44","author":"EI Deryugina","year":"2015","unstructured":"Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol. 2015;44:94\u2013112. https:\/\/doi.org\/10.1016\/j.matbio.2015.04.004.","journal-title":"Matrix Biol"},{"issue":"1","key":"1927_CR175","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1038\/s41467-023-38093-5","volume":"14","author":"EH Puttock","year":"2023","unstructured":"Puttock EH, Tyler EJ, Manni M, Maniati E, Butterworth C, Burger Ramos M, et al. Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis. Nat Commun. 2023;14(1):2514. https:\/\/doi.org\/10.1038\/s41467-023-38093-5.","journal-title":"Nat Commun"},{"key":"1927_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175087","volume":"928","author":"M Tajaldini","year":"2022","unstructured":"Tajaldini M, Saeedi M, Amiriani T, Amiriani AH, Sedighi S, Mohammad Zadeh F, et al. Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs); where do they stand in tumorigenesis and how they can change the face of cancer therapy? Eur J Pharmacol. 2022;928:175087. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175087.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1927_CR177","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170(4):605\u201335. https:\/\/doi.org\/10.1016\/j.cell.2017.07.029.","journal-title":"Cell"},{"issue":"1","key":"1927_CR178","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21(1):104. https:\/\/doi.org\/10.1186\/s12943-022-01569-x.","journal-title":"Mol Cancer"},{"issue":"19","key":"1927_CR179","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202416523","volume":"12","author":"W Li","year":"2025","unstructured":"Li W, Wu Y, Zhang Y, Gao W, Li X, Luo H, et al. Halofuginone disrupted collagen deposition via mTOR-eIF2\u03b1-ATF4 axis to enhance chemosensitivity in ovarian cancer. Adv Sci. 2025;12(19):e2416523. https:\/\/doi.org\/10.1002\/advs.202416523.","journal-title":"Adv Sci"},{"key":"1927_CR180","doi-asserted-by":"publisher","unstructured":"Chen D, Li B, Lei T, Na D, Nie M, Yang Y, Congjia, Xie, He Z, Wang J. Selective mediation of ovarian cancer SKOV3 cells death by pristine carbon quantum dots\/Cu2O composite through targeting matrix metalloproteinases, angiogenic cytokines and cytoskeleton. J Nanobiotechnology. 2021;19(1):68. https:\/\/doi.org\/10.1186\/s12951-021-00813-8.","DOI":"10.1186\/s12951-021-00813-8"},{"issue":"1","key":"1927_CR181","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12964-024-01648-0","volume":"22","author":"A Nasimi Shad","year":"2024","unstructured":"Nasimi Shad A, Moghbeli M. Integrins as the pivotal regulators of cisplatin response in tumor cells. Cell Commun Signal. 2024;22(1):265. https:\/\/doi.org\/10.1186\/s12964-024-01648-0.","journal-title":"Cell Commun Signal"},{"issue":"7","key":"1927_CR182","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9070083","volume":"9","author":"M Kobayashi","year":"2017","unstructured":"Kobayashi M, Sawada K, Kimura T. Potential of integrin inhibitors for treating ovarian cancer: a literature review. Cancers (Basel). 2017;9(7):83. https:\/\/doi.org\/10.3390\/cancers9070083.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1927_CR183","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Th\u00e9ry","year":"2018","unstructured":"Th\u00e9ry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750. https:\/\/doi.org\/10.1080\/20013078.2018.1535750.","journal-title":"J Extracell Vesicles"},{"issue":"2","key":"1927_CR184","doi-asserted-by":"publisher","first-page":"e12404","DOI":"10.1002\/jev2.12404","volume":"13","author":"JA Welsh","year":"2024","unstructured":"Welsh JA, Goberdhan DCI, O\u2019Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. https:\/\/doi.org\/10.1002\/jev2.12404.","journal-title":"J Extracell Vesicles"},{"issue":"6478","key":"1927_CR185","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. https:\/\/doi.org\/10.1126\/science.aau6977.","journal-title":"Science"},{"issue":"22","key":"1927_CR186","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212204","volume":"22","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Zhang Y, Gong H, Luo S, Cui Y. The role of exosomes and their applications in cancer. Int J Mol Sci. 2021;22(22):12204. https:\/\/doi.org\/10.3390\/ijms222212204.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1927_CR187","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040823","volume":"12","author":"D Pascut","year":"2020","unstructured":"Pascut D, Pratama MY, Vo NVT, Masadah R, Tiribelli C. The crosstalk between tumor cells and the microenvironment in hepatocellular carcinoma: the role of exosomal microRNAs and their clinical implications. Cancers (Basel). 2020;12(4):823. https:\/\/doi.org\/10.3390\/cancers12040823.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1927_CR188","doi-asserted-by":"publisher","first-page":"11917","DOI":"10.18632\/oncotarget.14440","volume":"8","author":"J Crow","year":"2017","unstructured":"Crow J, Atay S, Banskota S, Artale B, Schmitt S, Godwin AK. Exosomes as mediators of platinum resistance in ovarian cancer. Oncotarget. 2017;8(7):11917\u201336. https:\/\/doi.org\/10.18632\/oncotarget.14440.","journal-title":"Oncotarget"},{"issue":"7","key":"1927_CR189","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/s41388-019-1087-9","volume":"39","author":"M Asare-Werehene","year":"2020","unstructured":"Asare-Werehene M, Nakka K, Reunov A, Chiu CT, Lee WT, Abedini MR, et al. The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance. Oncogene. 2020;39(7):1600\u201316. https:\/\/doi.org\/10.1038\/s41388-019-1087-9.","journal-title":"Oncogene"},{"issue":"18","key":"1927_CR190","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1158\/0008-5472.CAN-20-0788","volume":"80","author":"M Asare-Werehene","year":"2020","unstructured":"Asare-Werehene M, Communal L, Carmona E, Han Y, Song YS, Burger D, et al. Plasma gelsolin inhibits CD8+ T-cell function and regulates glutathione production to confer chemoresistance in ovarian cancer. Cancer Res. 2020;80(18):3959\u201371. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-0788.","journal-title":"Cancer Res"},{"issue":"2","key":"1927_CR191","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1582-4934.2011.01316.x","volume":"16","author":"J Yin","year":"2012","unstructured":"Yin J, Yan X, Yao X, Zhang Y, Shan Y, Mao N, et al. Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients. J Cell Mol Med. 2012;16(2):337\u201348. https:\/\/doi.org\/10.1111\/j.1582-4934.2011.01316.x.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"1927_CR192","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/cbf.3276","volume":"35","author":"YL Cao","year":"2017","unstructured":"Cao YL, Zhuang T, Xing BH, Li N, Li Q. Exosomal DNMT1 mediates cisplatin resistance in ovarian cancer. Cell Biochem Funct. 2017;35(6):296\u2013303. https:\/\/doi.org\/10.1002\/cbf.3276.","journal-title":"Cell Biochem Funct"},{"issue":"9","key":"1927_CR193","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-023-04906-5","volume":"80","author":"Y Wu","year":"2023","unstructured":"Wu Y, Xu M, Feng Z, Wu H, Wu J, Ha X, et al. AUF1-induced circular RNA hsa_circ_0010467 promotes platinum resistance of ovarian cancer through miR-637\/LIF\/STAT3 axis. Cell Mol Life Sci. 2023;80(9):256. https:\/\/doi.org\/10.1007\/s00018-023-04906-5.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"1927_CR194","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.3802\/jgo.2020.31.e75","volume":"31","author":"Y Luo","year":"2020","unstructured":"Luo Y, Gui R. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells. J Gynecol Oncol. 2020;31(5):e75. https:\/\/doi.org\/10.3802\/jgo.2020.31.e75.","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"1927_CR195","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.3802\/jgo.2024.35.e13","volume":"35","author":"H Wang","year":"2024","unstructured":"Wang H, Li Y, Wang Y, Shang X, Yan Z, Li S, et al. Cisplatin-induced PANDAR-chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4\/SIRT6 axis. J Gynecol Oncol. 2024;35(2):e13. https:\/\/doi.org\/10.3802\/jgo.2024.35.e13.","journal-title":"J Gynecol Oncol"},{"issue":"9","key":"1927_CR196","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3390\/biom14091099","volume":"14","author":"M Shao","year":"2024","unstructured":"Shao M, Gao Y, Xu X, Chan DW, Du J. Exosomes: key factors in ovarian cancer peritoneal metastasis and drug resistance. Biomolecules. 2024;14(9):1099. https:\/\/doi.org\/10.3390\/biom14091099.","journal-title":"Biomolecules"},{"issue":"5","key":"1927_CR197","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3892\/ol.2021.12638","volume":"21","author":"X Li","year":"2021","unstructured":"Li X, Liu Y, Zheng S, Zhang T, Wu J, Sun Y, et al. Role of exosomes in the immune microenvironment of ovarian cancer. Oncol Lett. 2021;21(5):377. https:\/\/doi.org\/10.3892\/ol.2021.12638.","journal-title":"Oncol Lett"},{"issue":"1","key":"1927_CR198","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12964-024-01806-4","volume":"22","author":"ME Williams","year":"2024","unstructured":"Williams ME, Howard D, Donnelly C, Izadi F, Parra JG, Pugh M, et al. Adipocyte derived exosomes promote cell invasion and challenge paclitaxel efficacy in ovarian cancer. Cell Commun Signal. 2024;22(1):443. https:\/\/doi.org\/10.1186\/s12964-024-01806-4.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"1927_CR199","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-020-00758-w","volume":"14","author":"Z Li","year":"2021","unstructured":"Li Z, Yan-Qing W, Xiao Y, Shi-Yi L, Meng-Qin Y, Shu X, et al. Exosomes secreted by chemoresistant ovarian cancer cells promote angiogenesis. J Ovarian Res. 2021;14(1):7. https:\/\/doi.org\/10.1186\/s13048-020-00758-w.","journal-title":"J Ovarian Res"},{"issue":"10","key":"1927_CR200","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1158\/1535-7163","volume":"4","author":"R Safaei","year":"2005","unstructured":"Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 2005;4(10):1595\u2013604. https:\/\/doi.org\/10.1158\/1535-7163.","journal-title":"Mol Cancer Ther"},{"key":"1927_CR201","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejphar.2014.05.026","volume":"738","author":"FF Zhang","year":"2014","unstructured":"Zhang FF, Zhu YF, Zhao QN, Yang DT, Dong YP, Jiang L, et al. Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance. Eur J Pharmacol. 2014;738:83\u201390. https:\/\/doi.org\/10.1016\/j.ejphar.2014.05.026.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1927_CR202","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41420-021-00489-x","volume":"7","author":"L Qian","year":"2021","unstructured":"Qian L, Yang X, Li S, Zhao H, Gao Y, Zhao S, et al. Reduced O-GlcNAcylation of SNAP-23 promotes cisplatin resistance by inducing exosome secretion in ovarian cancer. Cell Death Discov. 2021;7(1):112. https:\/\/doi.org\/10.1038\/s41420-021-00489-x.","journal-title":"Cell Death Discov"},{"issue":"1","key":"1927_CR203","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ygyno.2021.10.076","volume":"164","author":"CA Calo","year":"2022","unstructured":"Calo CA, Smith BQ, Dorayappan KDP, Saini U, Lightfoot M, Wagner V, et al. Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: an implication for the antitumor potential of DAP compound. Gynecol Oncol. 2022;164(1):136\u201345. https:\/\/doi.org\/10.1016\/j.ygyno.2021.10.076.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1927_CR204","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13395-021-00274-5","volume":"11","author":"L Zhou","year":"2021","unstructured":"Zhou L, Zhang T, Shao W, Lu R, Wang L, Liu H, et al. Amiloride ameliorates muscle wasting in cancer cachexia through inhibiting tumor-derived exosome release. Skelet Muscle. 2021;11(1):17. https:\/\/doi.org\/10.1186\/s13395-021-00274-5.","journal-title":"Skelet Muscle"},{"issue":"1","key":"1927_CR205","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2019.1703244","volume":"9","author":"M Catalano","year":"2019","unstructured":"Catalano M, O\u2019Driscoll L. Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J Extracell Vesicles. 2019;9(1):1703244. https:\/\/doi.org\/10.1080\/20013078.2019.1703244.","journal-title":"J Extracell Vesicles"},{"key":"1927_CR206","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1479-5876-10-134","volume":"10","author":"AM Marleau","year":"2012","unstructured":"Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med. 2012;10:134. https:\/\/doi.org\/10.1186\/1479-5876-10-134.","journal-title":"J Transl Med"},{"issue":"7","key":"1927_CR207","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.biomaterials.2013.11.083","volume":"35","author":"Y Tian","year":"2014","unstructured":"Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35(7):2383\u201390. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.11.083.","journal-title":"Biomaterials"},{"key":"1927_CR208","doi-asserted-by":"publisher","first-page":"553576","DOI":"10.3389\/fcell.2020.553576","volume":"8","author":"S Pisano","year":"2020","unstructured":"Pisano S, Pierini I, Gu J, Gazze A, Francis LW, Gonzalez D, et al. Immune (cell) derived exosome mimetics (IDEM) as a treatment for ovarian cancer. Front Cell Dev Biol. 2020;8:553576. https:\/\/doi.org\/10.3389\/fcell.2020.553576.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1927_CR209","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apsb.2020.09.016","volume":"11","author":"H Duan","year":"2021","unstructured":"Duan H, Liu Y, Gao Z, Huang W. Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharm Sin B. 2021;11(1):55\u201370. https:\/\/doi.org\/10.1016\/j.apsb.2020.09.016.","journal-title":"Acta Pharm Sin B"},{"issue":"11","key":"1927_CR210","doi-asserted-by":"publisher","first-page":"5440","DOI":"10.1021\/acs.molpharmaceut.3c00132","volume":"20","author":"X Zhang","year":"2023","unstructured":"Zhang X, Wang J, Liu N, Wu W, Li H, Lu W, et al. Umbilical cord blood-derived M1 macrophage exosomes loaded with Cisplatin target ovarian cancer in vivo and reverse Cisplatin resistance. Mol Pharm. 2023;20(11):5440\u201353. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00132.","journal-title":"Mol Pharm"},{"key":"1927_CR211","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.canlet.2022.01.011","volume":"530","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Shuang T, Gao Y, Lu F, Zhang J, He W, et al. Targeted delivery of exosomal miR-484 reprograms tumor vasculature for chemotherapy sensitization. Cancer Lett. 2022;530:45\u201358. https:\/\/doi.org\/10.1016\/j.canlet.2022.01.011.","journal-title":"Cancer Lett"},{"issue":"1","key":"1927_CR212","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12951-022-01264-5","volume":"20","author":"L Li","year":"2022","unstructured":"Li L, He D, Guo Q, Zhang Z, Ru D, Wang L, et al. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. J Nanobiotechnol. 2022;20(1):50. https:\/\/doi.org\/10.1186\/s12951-022-01264-5.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"1927_CR213","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13048-024-01430-3","volume":"17","author":"M Wang","year":"2024","unstructured":"Wang M, Sun Y, Gu R, Tang Y, Han G, Zhao S. Shikonin reduces M2 macrophage population in ovarian cancer by repressing exosome production and the exosomal galectin 3-mediated \u03b2-catenin activation. J Ovarian Res. 2024;17(1):101. https:\/\/doi.org\/10.1186\/s13048-024-01430-3.","journal-title":"J Ovarian Res"},{"key":"1927_CR214","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2017.09.013","volume":"266","author":"SM Kim","year":"2017","unstructured":"Kim SM, Yang Y, Oh SJ, Hong Y, Seo M, Jang M. Cancer-derived exosomes as a delivery platform of CRISPR\/Cas9 confer cancer cell tropism-dependent targeting. J Control Release. 2017;266:8\u201316. https:\/\/doi.org\/10.1016\/j.jconrel.2017.09.013.","journal-title":"J Control Release"},{"issue":"1","key":"1927_CR215","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"X Jing","year":"2019","unstructured":"Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157. https:\/\/doi.org\/10.1186\/s12943-019-1089-9.","journal-title":"Mol Cancer"},{"key":"1927_CR216","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.semcancer.2017.01.008","volume":"43","author":"I Kolosenko","year":"2017","unstructured":"Kolosenko I, Avnet S, Baldini N, Viklund J, De Milito A. Therapeutic implications of tumor interstitial acidification. Semin Cancer Biol. 2017;43:119\u201333. https:\/\/doi.org\/10.1016\/j.semcancer.2017.01.008.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1927_CR217","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41598-024-84290-7","volume":"15","author":"X Chang","year":"2025","unstructured":"Chang X, Tamauchi S, Nakagawa A, Xinyuan W, Yoshida K, Yokoi A, et al. Chemotherapeutic hormesis induced by the tumor microenvironment in refractory ovarian cancer. Sci Rep. 2025;15(1):596. https:\/\/doi.org\/10.1038\/s41598-024-84290-7.","journal-title":"Sci Rep"},{"issue":"24","key":"1927_CR218","first-page":"7106","volume":"60","author":"C Blancher","year":"2000","unstructured":"Blancher C, Moore JW, Talks KL, Houlbrook S, Harris AL. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 2000;60(24):7106\u201313.","journal-title":"Cancer Res"},{"issue":"12","key":"1927_CR219","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126702","volume":"23","author":"DC Stieg","year":"2022","unstructured":"Stieg DC, Wang Y, Liu LZ, Jiang BH. ROS and miRNA dysregulation in ovarian cancer development, angiogenesis and therapeutic resistance. Int J Mol Sci. 2022;23(12):6702. https:\/\/doi.org\/10.3390\/ijms23126702.","journal-title":"Int J Mol Sci"},{"key":"1927_CR220","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2147\/CMAR.S414703","volume":"15","author":"M Yin","year":"2023","unstructured":"Yin M, Lu C, Zhou H, Liu Q, Yang J. Fibroblast growth factor 11 (FGF11) promotes progression and cisplatin resistance through the HIF-1\u03b1\/FGF11 signaling axis in ovarian clear cell carcinoma. Cancer Manag Res. 2023;15:753\u201363. https:\/\/doi.org\/10.2147\/CMAR.S414703.","journal-title":"Cancer Manag Res"},{"issue":"7","key":"1927_CR221","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.3390\/cells10071647","volume":"10","author":"WJ Liu","year":"2021","unstructured":"Liu WJ, Huang YX, Wang W, Zhang Y, Liu BJ, Qiu JG, et al. Nox4 signaling mediates cancer development and therapeutic resistance through HER3 in ovarian cancer cells. Cells. 2021;10(7):1647. https:\/\/doi.org\/10.3390\/cells10071647.","journal-title":"Cells"},{"issue":"4","key":"1927_CR222","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","volume":"33","author":"GL Semenza","year":"2012","unstructured":"Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33(4):207\u201314. https:\/\/doi.org\/10.1016\/j.tips.2012.01.005.","journal-title":"Trends Pharmacol Sci"},{"issue":"34","key":"1927_CR223","doi-asserted-by":"publisher","first-page":"55624","DOI":"10.18632\/oncotarget.10954","volume":"7","author":"EJ Seo","year":"2016","unstructured":"Seo EJ, Kim DK, Jang IH, Choi EJ, Shin SH, Lee SI, et al. Hypoxia-NOTCH1-SOX2 signaling is important for maintaining cancer stem cells in ovarian cancer. Oncotarget. 2016;7(34):55624\u201338. https:\/\/doi.org\/10.18632\/oncotarget.10954.","journal-title":"Oncotarget"},{"issue":"2","key":"1927_CR224","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/1878-0261.12419","volume":"13","author":"M He","year":"2019","unstructured":"He M, Wu H, Jiang Q, Liu Y, Han L, Yan Y, et al. Hypoxia-inducible factor-2\u03b1 directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin. Mol Oncol. 2019;13(2):403\u201321. https:\/\/doi.org\/10.1002\/1878-0261.12419.","journal-title":"Mol Oncol"},{"issue":"1","key":"1927_CR225","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41419-025-07646-5","volume":"16","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Yu X, Wen L, Wang J, Li Z, Zhang Y, et al. USP9X integrates TGF-\u03b2 and hypoxia signalings to promote ovarian cancer chemoresistance via HIF-2\u03b1-maintained stemness. Cell Death Dis. 2025;16(1):312. https:\/\/doi.org\/10.1038\/s41419-025-07646-5.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1927_CR226","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1038\/s41598-024-53854-y","volume":"14","author":"S Ma","year":"2024","unstructured":"Ma S, Wang J, Cui Z, Yang X, Cui X, Li X, et al. HIF-2\u03b1-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K\/Akt pathway to inhibit apoptosis and facilitate DNA repair process. Sci Rep. 2024;14(1):3870. https:\/\/doi.org\/10.1038\/s41598-024-53854-y.","journal-title":"Sci Rep"},{"issue":"45","key":"1927_CR227","doi-asserted-by":"publisher","first-page":"7089","DOI":"10.1038\/s41388-019-0949-5","volume":"38","author":"Y Han","year":"2019","unstructured":"Han Y, Kim B, Cho U, Park IS, Kim SI, Dhanasekaran DN, et al. Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells. Oncogene. 2019;38(45):7089\u2013105. https:\/\/doi.org\/10.1038\/s41388-019-0949-5.","journal-title":"Oncogene"},{"issue":"9","key":"1927_CR228","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1691\/ph.2018.8514","volume":"73","author":"F Long","year":"2018","unstructured":"Long F, Liu W, Jia P, Wang H, Jiang G, Wang T. HIF-1\u03b1-induced autophagy contributes to cisplatin resistance in ovarian cancer cells. Pharmazie. 2018;73(9):533\u20136. https:\/\/doi.org\/10.1691\/ph.2018.8514.","journal-title":"Pharmazie"},{"issue":"4","key":"1927_CR229","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.7150\/thno.29673","volume":"9","author":"X Zhang","year":"2019","unstructured":"Zhang X, Qi Z, Yin H, Yang G. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1\u03b1-mediated regulation of apoptosis and autophagy. Theranostics. 2019;9(4):1096\u2013114. https:\/\/doi.org\/10.7150\/thno.29673.","journal-title":"Theranostics"},{"key":"1927_CR230","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00381","volume":"9","author":"YM Salinas-Vera","year":"2019","unstructured":"Salinas-Vera YM, Gallardo-Rinc\u00f3n D, Garc\u00eda-V\u00e1zquez R, de la Hern\u00e1ndez- Cruz ON, Marchat LA, Gonz\u00e1lez-Barrios JA, et al. HypoxamiRs profiling identify miR-765 as a regulator of the early stages of vasculogenic mimicry in SKOV3 ovarian cancer cells. Front Oncol. 2019;9:381. https:\/\/doi.org\/10.3389\/fonc.2019.00381.","journal-title":"Front Oncol"},{"issue":"28","key":"1927_CR231","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1038\/s41388-018-0189-0","volume":"37","author":"KDP Dorayappan","year":"2018","unstructured":"Dorayappan KDP, Wanner R, Wallbillich JJ, Saini U, Zingarelli R, Suarez AA, et al. Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3\/Rab proteins. Oncogene. 2018;37(28):3806\u201321. https:\/\/doi.org\/10.1038\/s41388-018-0189-0.","journal-title":"Oncogene"},{"key":"1927_CR232","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100681","volume":"49","author":"J Dong","year":"2020","unstructured":"Dong J, Qin Z, Zhang WD, Cheng G, Yehuda AG, Ashby CR Jr, et al. Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update. Drug Resist Updat. 2020;49:100681. https:\/\/doi.org\/10.1016\/j.drup.2020.100681.","journal-title":"Drug Resist Updat"},{"issue":"19","key":"1927_CR233","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","volume":"26","author":"J Sehouli","year":"2008","unstructured":"Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008;26(19):3176\u201382. https:\/\/doi.org\/10.1200\/JCO.2007.15.1258.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1927_CR234","doi-asserted-by":"publisher","first-page":"e0248019","DOI":"10.1371\/journal.pone.0248019","volume":"16","author":"J Ni","year":"2021","unstructured":"Ni J, Ni A. Histone deacetylase inhibitor induced pVHL-independent degradation of HIF-1\u03b1 and hierarchical quality control of pVHL via chaperone system. PLoS One. 2021;16(7):e0248019. https:\/\/doi.org\/10.1371\/journal.pone.0248019.","journal-title":"PLoS One"},{"issue":"1","key":"1927_CR235","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3892\/ijo.2015.2987","volume":"47","author":"M Pastorek","year":"2015","unstructured":"Pastorek M, Simko V, Takacova M, Barathova M, Bartosova M, Hunakova L, et al. Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy. Int J Oncol. 2015;47(1):51\u201360. https:\/\/doi.org\/10.3892\/ijo.2015.2987.","journal-title":"Int J Oncol"},{"key":"1927_CR236","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/bs.ircmb.2020.01.005","volume":"354","author":"V Cocetta","year":"2020","unstructured":"Cocetta V, Ragazzi E, Montopoli M. Links between cancer metabolism and cisplatin resistance. Int Rev Cell Mol Biol. 2020;354:107\u201364. https:\/\/doi.org\/10.1016\/bs.ircmb.2020.01.005.","journal-title":"Int Rev Cell Mol Biol"},{"key":"1927_CR237","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1231460","volume":"13","author":"J Yan","year":"2023","unstructured":"Yan J, Xu F, Zhou D, Zhang S, Zhang B, Meng Q, et al. Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer. Front Oncol. 2023;13:1231460. https:\/\/doi.org\/10.3389\/fonc.2023.1231460.","journal-title":"Front Oncol"},{"issue":"1","key":"1927_CR238","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","volume":"23","author":"M Tufail","year":"2024","unstructured":"Tufail M, Jiang CH, Li N. Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol Cancer. 2024;23(1):203. https:\/\/doi.org\/10.1186\/s12943-024-02119-3.","journal-title":"Mol Cancer"},{"issue":"1","key":"1927_CR239","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.gde.2008.02.003","volume":"18","author":"RJ Deberardinis","year":"2008","unstructured":"Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008;18(1):54\u201361. https:\/\/doi.org\/10.1016\/j.gde.2008.02.003.","journal-title":"Curr Opin Genet Dev"},{"issue":"5","key":"1927_CR240","doi-asserted-by":"publisher","first-page":"a040535","DOI":"10.1101\/cshperspect.a040535","volume":"13","author":"NS Chandel","year":"2021","unstructured":"Chandel NS. Glycolysis. Cold Spring Harb Perspect Biol. 2021;13(5):a040535. https:\/\/doi.org\/10.1101\/cshperspect.a040535.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"1927_CR241","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188563","volume":"1876","author":"K Tyagi","year":"2021","unstructured":"Tyagi K, Mandal S, Roy A. Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: a promise towards disease remission. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2021;1876(1):188563. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188563.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"3","key":"1927_CR242","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189339","volume":"1880","author":"C Gao","year":"2025","unstructured":"Gao C, Li J, Shan B. Research progress on the regulatory role of lactate and lactylation in tumor microenvironment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025;1880(3):189339. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189339.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"2","key":"1927_CR243","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.bbrc.2018.06.092","volume":"503","author":"K Duan","year":"2018","unstructured":"Duan K, Liu ZJ, Hu SQ, Huo HY, Xu ZR, Ruan JF, et al. Lactic acid induces lactate transport and glycolysis\/OXPHOS interconversion in glioblastoma. Biochem Biophys Res Commun. 2018;503(2):888\u201394. https:\/\/doi.org\/10.1016\/j.bbrc.2018.06.092.","journal-title":"Biochem Biophys Res Commun"},{"key":"1927_CR244","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1480884","volume":"11","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Lou J, Tian Y, Ding J, Wang X, Tang B. How lactate affects immune strategies in lymphoma. Front Mol Biosci. 2024;11:1480884. https:\/\/doi.org\/10.3389\/fmolb.2024.1480884.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"1927_CR245","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41577-020-0406-2","volume":"21","author":"M Certo","year":"2021","unstructured":"Certo M, Tsai CH, Pucino V, Ho PC, Mauro C. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21(3):151\u201361. https:\/\/doi.org\/10.1038\/s41577-020-0406-2.","journal-title":"Nat Rev Immunol"},{"key":"1927_CR246","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.03.001","volume":"38","author":"P Icard","year":"2018","unstructured":"Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M, Lincet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat. 2018;38:1\u201311. https:\/\/doi.org\/10.1016\/j.drup.2018.03.001.","journal-title":"Drug Resist Updat"},{"issue":"6","key":"1927_CR247","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s10565-021-09650-9","volume":"38","author":"X Li","year":"2022","unstructured":"Li X, Zhang Y, Wang X, Lin F, Cheng X, Wang Z, et al. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2. Cell Biol Toxicol. 2022;38(6):1027\u201345. https:\/\/doi.org\/10.1007\/s10565-021-09650-9.","journal-title":"Cell Biol Toxicol"},{"key":"1927_CR248","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120328","volume":"293","author":"X Wu","year":"2022","unstructured":"Wu X, Qiu L, Feng H, Zhang H, Yu H, Du Y, et al. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG\/CLDN6 signaling in epithelial ovarian cancer. Life Sci. 2022;293:120328. https:\/\/doi.org\/10.1016\/j.lfs.2022.120328.","journal-title":"Life Sci"},{"issue":"15","key":"1927_CR249","doi-asserted-by":"publisher","first-page":"6928","DOI":"10.7150\/thno.43811","volume":"10","author":"H Sun","year":"2020","unstructured":"Sun H, Wang H, Wang X, Aoki Y, Wang X, Yang Y, et al. Aurora-A\/SOX8\/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells. Theranostics. 2020;10(15):6928\u201345. https:\/\/doi.org\/10.7150\/thno.43811.","journal-title":"Theranostics"},{"issue":"3","key":"1927_CR250","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3892\/ijo.2018.4476","volume":"53","author":"Y Xu","year":"2018","unstructured":"Xu Y, Gao W, Zhang Y, Wu S, Liu Y, Deng X, et al. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells. Int J Oncol. 2018;53(3):1055\u201368. https:\/\/doi.org\/10.3892\/ijo.2018.4476.","journal-title":"Int J Oncol"},{"key":"1927_CR251","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117452","volume":"180","author":"TY Lin","year":"2024","unstructured":"Lin TY, Gu SY, Lin YH, Shih JH, Lin JH, Chou TY, et al. Paclitaxel-resistance facilitates glycolytic metabolism via Hexokinase-2-regulated ABC and SLC transporter genes in ovarian clear cell carcinoma. Biomed Pharmacother. 2024;180:117452. https:\/\/doi.org\/10.1016\/j.biopha.2024.117452.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1927_CR252","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12943-025-02295-w","volume":"24","author":"B Lu","year":"2025","unstructured":"Lu B, Chen S, Guan X, Chen X, Du Y, Yuan J, et al. Lactate accumulation induces H4K12la to activate super-enhancer-driven RAD23A expression and promote niraparib resistance in ovarian cancer. Mol Cancer. 2025;24(1):83. https:\/\/doi.org\/10.1186\/s12943-025-02295-w.","journal-title":"Mol Cancer"},{"issue":"30","key":"1927_CR253","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202503999","volume":"12","author":"F Xie","year":"2025","unstructured":"Xie F, Zhang H, Dai X, Tu M, Yu C, Liu L, et al. HPD is an RNA-binding protein sustaining ovarian cancer cell glycolysis, tumor growth, and drug resistance. Adv Sci. 2025;e03999. https:\/\/doi.org\/10.1002\/advs.202503999.","journal-title":"Adv Sci"},{"key":"1927_CR254","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.semcancer.2022.11.007","volume":"87","author":"D Sharma","year":"2022","unstructured":"Sharma D, Singh M, Rani R. Role of LDH in tumor glycolysis: regulation of LDHA by small molecules for cancer therapeutics. Semin Cancer Biol. 2022;87:184\u201395. https:\/\/doi.org\/10.1016\/j.semcancer.2022.11.007.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"1927_CR255","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.7150\/ijbs.44343","volume":"16","author":"IH Tae","year":"2020","unstructured":"Tae IH, Son JY, Lee SH, Ahn MY, Yoon K, Yoon S, et al. A new SIRT1 inhibitor, MHY2245, induces autophagy and inhibits energy metabolism via PKM2\/mTOR pathway in human ovarian cancer cells. Int J Biol Sci. 2020;16(11):1901\u201316. https:\/\/doi.org\/10.7150\/ijbs.44343.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"1927_CR256","doi-asserted-by":"publisher","DOI":"10.1002\/smsc.202300192","volume":"4","author":"W Zhou","year":"2024","unstructured":"Zhou W, Ma X, Xiao J, He X, Liu C, Xu X, et al. Exploiting the Warburg effect: co-delivery of Metformin and FOXK2 siRNA for ovarian cancer therapy. Small Science. 2024;4(3):2300192. https:\/\/doi.org\/10.1002\/smsc.202300192.","journal-title":"Small Science"},{"issue":"1","key":"1927_CR257","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/molecules29010075","volume":"29","author":"B Liu","year":"2023","unstructured":"Liu B, Lu Y, Taledaohan A, Qiao S, Li Q, Wang Y. The promoting role of HK II in tumor development and the research progress of its inhibitors. Molecules. 2023;29(1):75. https:\/\/doi.org\/10.3390\/molecules29010075.","journal-title":"Molecules"},{"issue":"4","key":"1927_CR258","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20040840","volume":"20","author":"C Roma-Rodrigues","year":"2019","unstructured":"Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840. https:\/\/doi.org\/10.3390\/ijms20040840.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"1927_CR259","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315348121","volume":"121","author":"Y Nan","year":"2024","unstructured":"Nan Y, Wu X, Luo Q, Chang W, Zhao P, Zhang L, et al. Otub2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition. Proc Natl Acad Sci U S A. 2024;121(19):e2315348121. https:\/\/doi.org\/10.1073\/pnas.2315348121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1927_CR260","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.canlet.2016.01.009","volume":"373","author":"Z Ai","year":"2016","unstructured":"Ai Z, Lu Y, Qiu S, Fan Z. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Lett. 2016;373(1):36\u201344. https:\/\/doi.org\/10.1016\/j.canlet.2016.01.009.","journal-title":"Cancer Lett"},{"key":"1927_CR261","doi-asserted-by":"publisher","first-page":"768","DOI":"10.18632\/oncotarget.28241","volume":"13","author":"S Chaudhry","year":"2022","unstructured":"Chaudhry S, Thomas SN, Simmons GE Jr. Targeting lipid metabolism in the treatment of ovarian cancer. Oncotarget. 2022;13:768\u201383. https:\/\/doi.org\/10.18632\/oncotarget.28241.","journal-title":"Oncotarget"},{"issue":"1","key":"1927_CR262","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201606","volume":"218","author":"X Bian","year":"2021","unstructured":"Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218(1):e20201606. https:\/\/doi.org\/10.1084\/jem.20201606.","journal-title":"J Exp Med"},{"issue":"17","key":"1927_CR263","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41388-017-0093-z","volume":"37","author":"A Ladanyi","year":"2018","unstructured":"Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018;37(17):2285\u2013301. https:\/\/doi.org\/10.1038\/s41388-017-0093-z.","journal-title":"Oncogene"},{"issue":"1","key":"1927_CR264","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13046-022-02315-3","volume":"41","author":"F Lin","year":"2022","unstructured":"Lin F, Li X, Wang X, Sun H, Wang Z, Wang X. Stanniocalcin 1 promotes metastasis, lipid metabolism and cisplatin chemoresistance via the FOXC2\/ITGB6 signaling axis in ovarian cancer. J Exp Clin Cancer Res. 2022;41(1):129. https:\/\/doi.org\/10.1186\/s13046-022-02315-3.","journal-title":"J Exp Clin Cancer Res"},{"issue":"14","key":"1927_CR265","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1158\/1078-0432.CCR-19-3790","volume":"26","author":"J Li","year":"2020","unstructured":"Li J, Pan C, Boese AC, Kang J, Umano AD, Magliocca KR, et al. DGKA provides platinum resistance in ovarian cancer through activation of c-JUN-WEE1 signaling. Clin Cancer Res. 2020;26(14):3843\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3790.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1927_CR266","doi-asserted-by":"publisher","first-page":"13316","DOI":"10.1038\/s41598-019-49649-1","volume":"9","author":"J Yang","year":"2019","unstructured":"Yang J, Zaman MM, Vlasakov I, Roy R, Huang L, Martin CR, et al. Adipocytes promote ovarian cancer chemoresistance. Sci Rep. 2019;9(1):13316. https:\/\/doi.org\/10.1038\/s41598-019-49649-1.","journal-title":"Sci Rep"},{"issue":"8","key":"1927_CR267","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1172\/JCI127201","volume":"129","author":"Y Cao","year":"2019","unstructured":"Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest. 2019;129(8):3006\u201317. https:\/\/doi.org\/10.1172\/JCI127201.","journal-title":"J Clin Invest"},{"issue":"4","key":"1927_CR268","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41419-020-2442-z","volume":"11","author":"S Nallanthighal","year":"2020","unstructured":"Nallanthighal S, Rada M, Heiserman JP, Cha J, Sage J, Zhou B, et al. Inhibition of collagen XI alpha 1-induced fatty acid oxidation triggers apoptotic cell death in cisplatin-resistant ovarian cancer. Cell Death Dis. 2020;11(4):258. https:\/\/doi.org\/10.1038\/s41419-020-2442-z.","journal-title":"Cell Death Dis"},{"issue":"11","key":"1927_CR269","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/nm.2492","volume":"17","author":"KM Nieman","year":"2011","unstructured":"Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498\u2013503. https:\/\/doi.org\/10.1038\/nm.2492.","journal-title":"Nat Med"},{"issue":"1","key":"1927_CR270","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13048-020-00718-4","volume":"13","author":"L Dai","year":"2020","unstructured":"Dai L, Song K, Di W. Adipocytes: active facilitators in epithelial ovarian cancer progression? J Ovarian Res. 2020;13(1):115. https:\/\/doi.org\/10.1186\/s13048-020-00718-4.","journal-title":"J Ovarian Res"},{"issue":"1","key":"1927_CR271","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41420-023-01385-2","volume":"9","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Li N, Deng L, Jiang X, Zhang Y, Lee LTO, et al. ACSL1-induced ferroptosis and platinum resistance in ovarian cancer by increasing FSP1 N-myristylation and stability. Cell Death Discov. 2023;9(1):83. https:\/\/doi.org\/10.1038\/s41420-023-01385-2.","journal-title":"Cell Death Discov"},{"issue":"3","key":"1927_CR272","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.stem.2016.11.004","volume":"20","author":"J Li","year":"2017","unstructured":"Li J, Condello S, Thomes-Pepin J, Ma X, Xia Y, Hurley TD, et al. Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell. 2017;20(3):303-314.e5. https:\/\/doi.org\/10.1016\/j.stem.2016.11.004.","journal-title":"Cell Stem Cell"},{"issue":"20","key":"1927_CR273","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1158\/0008-5472.CAN-19-0369","volume":"79","author":"L Tesfay","year":"2019","unstructured":"Tesfay L, Paul BT, Konstorum A, Deng Z, Cox AO, Lee J, et al. Stearoyl-CoA desaturase 1 protects ovarian cancer cells from ferroptotic cell death. Cancer Res. 2019;79(20):5355\u201366. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0369.","journal-title":"Cancer Res"},{"issue":"12","key":"1927_CR274","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3390\/cells12121605","volume":"12","author":"WW Feng","year":"2023","unstructured":"Feng WW, Zuppe HT, Kurokawa M. The role of CD36 in cancer progression and its value as a therapeutic target. Cells. 2023;12(12):1605. https:\/\/doi.org\/10.3390\/cells12121605.","journal-title":"Cells"},{"issue":"13","key":"1927_CR275","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202305212","volume":"11","author":"Y Wang","year":"2024","unstructured":"Wang Y, Calvert AE, Cardenas H, Rink JS, Nahotko D, Qiang W, et al. Nanoparticle targeting in chemo-resistant ovarian cancer reveals dual axis of therapeutic vulnerability involving cholesterol uptake and cell redox balance. Adv Sci. 2024;11(13):e2305212. https:\/\/doi.org\/10.1002\/advs.202305212.","journal-title":"Adv Sci"},{"key":"1927_CR276","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12967-015-0511-3","volume":"13","author":"DO Bauerschlag","year":"2015","unstructured":"Bauerschlag DO, Maass N, Leonhardt P, Verburg FA, Pecks U, Zeppernick F, et al. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer. J Transl Med. 2015;13:146. https:\/\/doi.org\/10.1186\/s12967-015-0511-3.","journal-title":"J Transl Med"},{"issue":"12","key":"1927_CR277","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100471","volume":"2","author":"D Huang","year":"2021","unstructured":"Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, et al. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Rep Med. 2021;2(12):100471. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100471.","journal-title":"Cell Rep Med"},{"issue":"25","key":"1927_CR278","doi-asserted-by":"publisher","first-page":"00186","DOI":"10.1016\/j.jare.2025.03.026","volume":"S2090\u20131232","author":"H Lin","year":"2025","unstructured":"Lin H, Wang L, Chen H, Shen Y, Wang C, Xue Y, et al. Mitochondrial fatty acid oxidation as the target for blocking therapy-resistance and inhibiting tumor recurrence: The proof-of-principle model demonstrated for ovarian cancer cells. J Adv Res. 2025;S2090\u20131232(25):00186\u20139. https:\/\/doi.org\/10.1016\/j.jare.2025.03.026.","journal-title":"J Adv Res"},{"key":"1927_CR279","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fcell.2019.00086","volume":"7","author":"S Nallanthighal","year":"2019","unstructured":"Nallanthighal S, Heiserman JP, Cheon DJ. The role of the extracellular matrix in cancer stemness. Front Cell Dev Biol. 2019;7:86. https:\/\/doi.org\/10.3389\/fcell.2019.00086.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1927_CR280","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12885-021-07879-5","volume":"21","author":"J Guo","year":"2021","unstructured":"Guo J, Satoh K, Tabata S, Mori M, Tomita M, Soga T. Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells. BMC Cancer. 2021;21(1):174. https:\/\/doi.org\/10.1186\/s12885-021-07879-5.","journal-title":"BMC Cancer"},{"key":"1927_CR281","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5864826","volume":"2022","author":"S You","year":"2022","unstructured":"You S, Zhu X, Yang Y, Du X, Song K, Zheng Q, et al. SLC7A1 overexpression is involved in energy metabolism reprogramming to induce tumor progression in epithelial ovarian cancer and is associated with immune-infiltrating cells. J Oncol. 2022;2022:5864826. https:\/\/doi.org\/10.1155\/2022\/5864826.","journal-title":"J Oncol"},{"issue":"4","key":"1927_CR282","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1530\/ERC-15-0192","volume":"22","author":"L Yuan","year":"2015","unstructured":"Yuan L, Sheng X, Willson AK, Roque DR, Stine JE, Guo H, et al. Glutamine promotes ovarian cancer cell proliferation through the mTOR\/S6 pathway. Endocr Relat Cancer. 2015;22(4):577\u201391. https:\/\/doi.org\/10.1530\/ERC-15-0192.","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"1927_CR283","doi-asserted-by":"publisher","first-page":"e002682","DOI":"10.1136\/jitc-2021-002682","volume":"9","author":"LE Sima","year":"2021","unstructured":"Sima LE, Chen S, Cardenas H, Zhao G, Wang Y, Ivan C, et al. Loss of host tissue transglutaminase boosts antitumor T cell immunity by altering STAT1\/STAT3 phosphorylation in ovarian cancer. J Immunother Cancer. 2021;9(9):e002682. https:\/\/doi.org\/10.1136\/jitc-2021-002682.","journal-title":"J Immunother Cancer"},{"issue":"14","key":"1927_CR284","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202416467","volume":"12","author":"C Zheng","year":"2025","unstructured":"Zheng C, Tan H, Niu G, Huang X, Lu J, Chen S, et al. ACAT1-mediated ME2 acetylation drives chemoresistance in ovarian cancer by linking glutaminolysis to lactate production. Adv Sci. 2025;12(14):e2416467. https:\/\/doi.org\/10.1002\/advs.202416467.","journal-title":"Adv Sci"},{"issue":"15","key":"1927_CR285","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158761","volume":"23","author":"G Kim","year":"2022","unstructured":"Kim G, Jang SK, Kim YJ, Jin HO, Bae S, Hong J, et al. Inhibition of glutamine uptake resensitizes paclitaxel resistance in SKOV3-TR ovarian cancer cell via mTORC1\/S6K signaling pathway. Int J Mol Sci. 2022;23(15):8761. https:\/\/doi.org\/10.3390\/ijms23158761.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"1927_CR286","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1158\/0008-5472.CAN-19-3971","volume":"80","author":"YA Shen","year":"2020","unstructured":"Shen YA, Hong J, Asaka R, Asaka S, Hsu FC, Suryo Rahmanto Y, et al. Inhibition of the MYC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant ovarian cancers. Cancer Res. 2020;80(20):4514\u201326. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3971.","journal-title":"Cancer Res"},{"key":"1927_CR287","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jconrel.2024.12.073","volume":"379","author":"S Chen","year":"2025","unstructured":"Chen S, Jiang Y, Zheng J, Li P, Liu M, Zhu Y, et al. Folate-targeted nanoparticles for glutamine metabolism inhibition enhance anti-tumor immunity and suppress tumor growth in ovarian cancer. J Control Release. 2025;379:89\u2013104. https:\/\/doi.org\/10.1016\/j.jconrel.2024.12.073.","journal-title":"J Control Release"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01927-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01927-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01927-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T09:56:20Z","timestamp":1768384580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-025-01927-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":287,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1927"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01927-5","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}